var title_f38_22_39264="Guideline for cervical spine clearance in the reliable child";
var content_f38_22_39264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Guideline for cervical spine clearance in the reliable pediatric patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 739px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     c-spine: cervical spine; AP: antero-posterior; D/C: discontinue; MRI: magnetic resonance imaging; CT: computed tomography.",
"     <br>",
"      * Awake and alert with GCS = 15.",
"      <br>",
"       &Delta; Meets NEXUS criteria (no midline cervical spine tenderness, no focal neurologic deficit, normal alertness, no intoxication, and no painful, distracting injury) AND moves head in flexion/extension AND rotate 45 degrees to both sides with no pain.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Change to long term cervical spine collar as soon as appropriate.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chung S, Mikrogianakis A, Wales PW, et al. Trauma Association of Canada Pediatric Subcommittee National Pediatric Cervical Spine Evaluation Pathway: Consensus Guidelines. J Trauma 2011; 70:873. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39264=[""].join("\n");
var outline_f38_22_39264=null;
var title_f38_22_39265="Mobilization of the splenic flexure";
var content_f38_22_39265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Mobilization of the splenic flexure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts mobilizing the splenic flexure, one of the challenging components of a left colectomy. The dissection progresses from the mid transverse colon medially to distally, a technique particularly helpful in obese patients or in settings when the splenic flexure cannot be safely approached and mobilized laterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39265=[""].join("\n");
var outline_f38_22_39265=null;
var title_f38_22_39266="Cystic breast mass US";
var content_f38_22_39266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasonography of a cystic breast mass in an adolescent patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nirupama K De Silva, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39266=[""].join("\n");
var outline_f38_22_39266=null;
var title_f38_22_39267="Cefepime: Patient drug information";
var content_f38_22_39267=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cefepime: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     see \"Cefepime: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/9/12438?source=see_link\">",
"     see \"Cefepime: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F147316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Maxipime&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cefepime or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11316 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39267=[""].join("\n");
var outline_f38_22_39267=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147316\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023880\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023879\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023884\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023885\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023887\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023882\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023883\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023888\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023889\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=related_link\">",
"      Cefepime: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/9/12438?source=related_link\">",
"      Cefepime: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_22_39268="Eczema herpeticum arm";
var content_f38_22_39268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eczema herpeticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Punched-out ulcers are due to herpes simplex virus infection present on the arm of this patient with underlying atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39268=[""].join("\n");
var outline_f38_22_39268=null;
var title_f38_22_39269="Pathogenesis of osteomyelitis";
var content_f38_22_39269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of osteomyelitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39269/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39269/contributors\">",
"     Jason Calhoun, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39269/contributors\">",
"     LiYan Yin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39269/contributors\">",
"     Madhuri M Sopirala, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39269/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39269/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39269/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39269/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/22/39269/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis is a progressive infection of bone that results in inflammatory destruction, followed by new bone formation. Three major categories are based upon pathogenic mechanisms of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteomyelitis secondary to a contiguous focus of infection (eg, after trauma, surgery, or insertion of a prosthetic joint)",
"     </li>",
"     <li>",
"      Osteomyelitis secondary to a contiguous focus of infection associated with vascular insufficiency, primarily occurring in patients with diabetes mellitus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peripheral vascular disease",
"     </li>",
"     <li>",
"      Osteomyelitis following hematogenous spread of infection, which is the major mechanism in vertebral osteomyelitis and in children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute osteomyelitis evolves over several days to weeks and can progress to a chronic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/1\">",
"     1",
"    </a>",
"    ]. The hallmark of chronic osteomyelitis is the presence of dead bone (sequestrum). Other common features of chronic osteomyelitis include involucrum (reactive bony encasement of the sequestrum), local bone loss, and, if there is extension through cortical bone, sinus tracts.",
"   </p>",
"   <p>",
"    The pathogenesis and pathology of acute and chronic osteomyelitis will be reviewed here. The diagnosis and treatment of osteomyelitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10646?source=see_link\">",
"     \"Treatment and prevention of osteomyelitis following trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal bone is highly resistant to infection. Thus, osteomyelitis arises only when there is a large organism inoculation, trauma leading to bone damage, or the presence of foreign material. The pathogenesis of osteomyelitis is multifactorial and poorly understood. Some important factors include: virulence of the infecting organism(s), underlying immune status of the host, and the type, location, and vascularity of the bone.",
"   </p>",
"   <p>",
"    Bacteria have a variety of virulence determinants that can contribute to the development of osteomyelitis in the appropriate clinical setting. As an example, Staphylococcus aureus, which is an important cause of both hematogenous and contiguous focus osteomyelitis, produces a number of extracellular and cell-associated factors that may contribute to virulence by promoting bacterial adherence, resistance to host defense mechanisms, and proteolytic activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bacterial adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adherence appears to play a central role in the early stages of S. aureus-induced osteomyelitis or arthritis. S. aureus adheres to a number of components of bone matrix including fibrinogen, fibronectin, laminin, collagen, bone sialoglycoprotein, and clumping factor A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Adherence is mediated by expression of specific adhesins, called microbial surface components recognizing adhesive matrix molecules (MSCRAMM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential importance of adhesins was illustrated in a study in which mice were inoculated with positive and negative mutants for the collagen adhesin gene: septic arthritis occurred with greater frequency in the mutant positive compared with mutant negative strains (&gt;70 percent versus 27 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/8\">",
"     8",
"    </a>",
"    ]. The adhesin positive strains were also associated with the production of high levels of IgG and interleukin-6. In other experimental studies, S. aureus adhesion was blocked by antibodies directed against the collagen receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/9\">",
"     9",
"    </a>",
"    ]. It has been speculated that bone and other invasive S. aureus infections might be prevented by an adhesin-derived vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Collagen-binding adhesin (CNA) of S. aureus is a virulence factor for arthritis in several animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The expression of CNA permits the attachment of pathogen to cartilage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/13\">",
"     13",
"    </a>",
"    ]. How CNA contributes to virulence and whether it is important in humans are unclear.",
"   </p>",
"   <p>",
"    Fibronectin-binding protein rapidly coats implanted foreign bodies in vivo and adheres to biomaterials coated with host proteins. It may be particularly important in infections associated with prosthetic joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/4\">",
"     4",
"    </a>",
"    ]. Atomic-force microscopy has demonstrated that fibronectin binding proteins A and B (FnBPA and FnBPB) form bonds with host fibronectin and may play a key role in binding S. aureus to implants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42680?source=see_link\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Proteolytic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential proteolytic activity present in normal joints is inhibited in the absence of infection. However, this protective effect may be lost with infection. In an in vitro model of adult chondrocytes inoculated with S. aureus, for example, overall protein synthesis was reduced by 84 percent, with an increase in the release of collagenase and gelatinase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Resistance to host defense",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of microorganisms to resist host defense mechanisms at both the cellular and matrix levels presents difficulties in the treatment of osteomyelitis.",
"   </p>",
"   <p>",
"    S. aureus can survive intracellularly in cultured osteoblasts. Persistence of intracellular pathogens within osteoblasts may also be an important factor in the pathogenesis of osteomyelitis. When digested by osteoblasts, S. aureus undergoes phenotypic alteration, which renders it more resistant to the action of antimicrobials. This may explain in part the high relapse rate of osteomyelitis treated with antimicrobials for a short duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Osteoblast persistence of S. aureus in chronic osteomyelitis has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arachidonic acid metabolites, such as prostaglandin E2, a strong osteoclast agonist, decrease the bacterial inoculum needed to produce infection.",
"   </p>",
"   <p>",
"    S. aureus expresses a 42-kDa protein, protein A, which is bound covalently to the outer peptidoglycan layer of their cell walls. Protein A binds to the Fc portion of IgG on polymorphonuclear leukocytes, interfering with opsonization and phagocytosis of S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/20\">",
"     20",
"    </a>",
"    ]. Loss of protein A activity reduces virulence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. aureus secretes two toxins, exotoxin and toxic shock syndrome toxin (TSST-1), which exert important effects on the immune system when administered parenterally. The toxins act as superantigens and suppress plasma cell differentiation; they also stimulate production of cytokines, such as interleukin-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/22\">",
"     22",
"    </a>",
"    ], interferon-gamma, and tumor necrosis factor-alpha (TNF-a) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/23\">",
"     23",
"    </a>",
"    ]. Animals infected with strains of S. aureus isogenic for TSST-1 develop frequent and severe arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/24\">",
"     24",
"    </a>",
"    ]. Staphylococcal enterotoxin and TSST-1 subvert the cellular and humoral immune system, which may determine whether a local infection is eliminated or develops into osteomyelitis or septic arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute osteomyelitis demonstrates suppurative infection with acute inflammatory cells, accompanied by edema, vascular congestion, and small vessel thrombosis (",
"    <a class=\"graphic graphic_picture graphicRef72714 \" href=\"mobipreview.htm?18/2/18468\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62981 \" href=\"mobipreview.htm?14/61/15315\">",
"     picture 2",
"    </a>",
"    ). In early acute disease, the vascular supply to the bone is compromised by infection extending into the surrounding soft tissue. When both the medullary and periosteal blood supplies are compromised, large areas of dead bone (sequestra) may form. Within this necrotic and ischemic tissue, bacteria can be difficult to eradicate even in the setting of an intense host response, surgery, and antibiotic therapy.",
"   </p>",
"   <p>",
"    Clinically and histologically, acute osteomyelitis blends into chronic osteomyelitis. Pathologic features of chronic osteomyelitis include necrotic bone, the formation of new bone, and polymorphonuclear leukocyte exudation joined by large numbers of lymphocytes, histiocytes, and occasional plasma cells (",
"    <a class=\"graphic graphic_picture graphicRef53767 \" href=\"mobipreview.htm?28/59/29619\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Necrosis of normal tissue is an important feature of osteomyelitis. Dead bone is absorbed by the action of granulation tissue developing at its surface. Absorption takes place earliest and most rapidly at the junction of living and necrotic bone. If the area of the dead bone is small, it is entirely destroyed by granulation tissue, leaving a cavity behind. The necrotic cancellous (trabecular) bone in localized osteomyelitis, even though extensive, is usually absorbed. Some of the dead cortical bone is gradually detached from living bone to form a sequestrum.",
"   </p>",
"   <p>",
"    Host defense and mesenchymal cells, mainly the polymorphonuclear leukocytes, macrophages, and the osteoclasts, elaborate proteolytic enzymes that break down organic elements in the dead bone (",
"    <a class=\"graphic graphic_picture graphicRef62981 \" href=\"mobipreview.htm?14/61/15315\">",
"     picture 2",
"    </a>",
"    ). Because of lost blood supply, dead bone appears whiter than living bone. Cancellous bone is absorbed rapidly and may be completely sequestrated or destroyed in two to three weeks, but necrotic cortex may require two weeks to six months for separation. After complete separation, the dead bone is slowly eroded by granulation tissue and absorbed.",
"   </p>",
"   <p>",
"    New bone formation is another characteristic feature of osteomyelitis. New bone forms from the surviving fragments of periosteum, endosteum, and the cortex in the region of the infection and is produced by a vascular reaction to the infection. New bone may be formed along the intact periosteal and endosteal surfaces, and may also arise when the periosteum forms an encasing sheath of live bone (involucrum) surrounding the dead bone. Involucrum is irregular and is often perforated by openings through which pus may track into the surrounding soft tissues and eventually to the skin surfaces through a sinus tract. The involucrum can gradually increase in density and thickness to form part or all of a new shaft.",
"   </p>",
"   <p>",
"    New bone increases in amount and density for weeks or months, according to the size of the bone and the extent and duration of infection. Endosteal new bone may proliferate and obstruct the medullary canal. After host defense removal or surgical removal of the sequestrum, the body, especially in children, may fill the remaining cavity with new bone. However, in adults, the cavity may persist or the space may be filled with fibrous tissue that may connect with the skin surface via a sinus tract.",
"   </p>",
"   <p>",
"    The surviving bone in the osteomyelitis field usually becomes osteoporotic during the active period of infection. Osteoporosis is the result of the inflammatory reaction and atrophy disuse. After the infection subsides, bone density increases partially from reuse (eg, of a limb); the bone may undergo extensive transformation to conform to areas of new mechanical stresses. It may be difficult to distinguish between the old living bone and the newly formed bone as time passes. All traces of osteomyelitis can disappear in children and, to a lesser extent, in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differences by age",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are basic differences in the pathology of osteomyelitis in infants, children, and adults.",
"   </p>",
"   <p>",
"    In neonates, small capillaries cross the epiphyseal growth plate and permit extension of infection into the epiphysis and joint space. The cortical bone of the neonate and infant is thin and loose, consisting predominantly of woven bone, which permits escape of the pressure caused by infection, but promotes rapid spread of the infection directly into the subperiosteal region. A large sequestrum is not produced because extensive infarction of the cortex does not occur; however, a large subperiosteal abscess can form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children older than one year, infection presumably starts in the metaphyseal sinusoidal veins and is contained by the growth plate. The joint is spared unless the metaphysis is intracapsular. The infection spreads laterally where it breaks through the cortex and lifts the loose periosteum to form a subperiosteal abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, the growth plate has resorbed, and the infection may again extend to the joint spaces as in infants. In addition, the periosteum is firmly attached to the underlying bone; as a result, subperiosteal abscess formation and intense periosteal proliferation are less frequently seen. The infection can erode through the periosteum, forming a draining sinus tract(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39269/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18562386\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hallmark of chronic osteomyelitis is the presence of dead bone (sequestrum). Other common features of chronic osteomyelitis include involucrum (reactive bony encasement of the sequestrum), local bone loss, and, if there is extension through cortical bone, sinus tracts. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of osteomyelitis is multifactorial and poorly understood. Some important factors include: virulence of the infecting organism(s), underlying immune status of the host, and the type, location, and vascularity of the bone. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staphylococcus aureus can survive intracellularly in cultured osteoblasts. Persistence of intracellular pathogens within osteoblasts may also be an important factor in the pathogenesis of osteomyelitis. When digested by osteoblasts, S. aureus undergoes phenotypic alteration which renders it more resistant to the action of antimicrobials. This may explain in part the high relapse rate of osteomyelitis treated with antimicrobials for a short duration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Resistance to host defense'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute osteomyelitis demonstrates suppurative infection with acute inflammatory cells, accompanied by edema, vascular congestion, and small vessel thrombosis (",
"      <a class=\"graphic graphic_picture graphicRef72714 \" href=\"mobipreview.htm?18/2/18468\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef62981 \" href=\"mobipreview.htm?14/61/15315\">",
"       picture 2",
"      </a>",
"      ). Pathologic features of chronic osteomyelitis include necrotic bone, the formation of new bone, and polymorphonuclear leukocyte exudation joined by large numbers of lymphocytes, histiocytes, and occasional plasma cells (",
"      <a class=\"graphic graphic_picture graphicRef53767 \" href=\"mobipreview.htm?28/59/29619\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New bone formation is another characteristic feature of osteomyelitis. New bone forms from the surviving fragments of periosteum, endosteum, and the cortex in the region of the infection and is produced by a vascular reaction to the infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The surviving bone in the osteomyelitis field usually becomes osteoporotic during the active period of infection. Osteoporosis is the result of the inflammatory reaction and atrophy disuse. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/1\">",
"      Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/2\">",
"      Foster TJ, H&ouml;&ouml;k M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998; 6:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/3\">",
"      Herrmann M, Vaudaux PE, Pittet D, et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. J Infect Dis 1988; 158:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/4\">",
"      Johansson A, Flock JI, Svensson O. Collagen and fibronectin binding in experimental staphylococcal osteomyelitis. Clin Orthop Relat Res 2001; :241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/5\">",
"      Yacoub A, Lindahl P, Rubin K, et al. Purification of a bone sialoprotein-binding protein from Staphylococcus aureus. Eur J Biochem 1994; 222:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/6\">",
"      Ryd&eacute;n C, Tung HS, Nikolaev V, et al. Staphylococcus aureus causing osteomyelitis binds to a nonapeptide sequence in bone sialoprotein. Biochem J 1997; 327 ( Pt 3):825.",
"     </a>",
"    </li>",
"    <li>",
"     Shirtliff ME, Leid JG, Costerton JW. The Basic Science of Musculoskeletal Infections. In: Musculoskeletal Infections, Calhoun JH, Mader JT (Eds), Marcel Decker, New York 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/8\">",
"      Patti JM, Bremell T, Krajewska-Pietrasik D, et al. The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect Immun 1994; 62:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/9\">",
"      Switalski LM, Patti JM, Butcher W, et al. A collagen receptor on Staphylococcus aureus strains isolated from patients with septic arthritis mediates adhesion to cartilage. Mol Microbiol 1993; 7:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/10\">",
"      Patti JM. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 2004; 22 Suppl 1:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/11\">",
"      Xu Y, Rivas JM, Brown EL, et al. Virulence potential of the staphylococcal adhesin CNA in experimental arthritis is determined by its affinity for collagen. J Infect Dis 2004; 189:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/12\">",
"      Therrien R, Lacasse P, Grondin G, Talbot BG. Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein. Vaccine 2007; 25:5053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/13\">",
"      Patti JM, Boles JO, H&ouml;&ouml;k M. Identification and biochemical characterization of the ligand binding domain of the collagen adhesin from Staphylococcus aureus. Biochemistry 1993; 32:11428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/14\">",
"      Buck AW, Fowler VG Jr, Yongsunthon R, et al. Bonds between fibronectin and fibronectin-binding proteins on Staphylococcus aureus and Lactococcus lactis. Langmuir 2010; 26:10764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/15\">",
"      Williams RJ 3rd, Smith RL, Schurman DJ. Septic arthritis. Staphylococcal induction of chondrocyte proteolytic activity. Arthritis Rheum 1990; 33:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/16\">",
"      Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/17\">",
"      Norden CW. Lessons learned from animal models of osteomyelitis. Rev Infect Dis 1988; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/18\">",
"      Webb LX, Wagner W, Carroll D, et al. Osteomyelitis and intraosteoblastic Staphylococcus aureus. J Surg Orthop Adv 2007; 16:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/19\">",
"      Ellington JK, Harris M, Hudson MC, et al. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res 2006; 24:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/20\">",
"      Greenberg DP, Bayer AS, Cheung AL, Ward JI. Protective efficacy of protein A-specific antibody against bacteremic infection due to Staphylococcus aureus in an infant rat model. Infect Immun 1989; 57:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/21\">",
"      Gemmell CG, Goutcher SC, Reid R, Sturrock RD. Role of certain virulence factors in a murine model of Staphylococcus aureus arthritis. J Med Microbiol 1997; 46:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/22\">",
"      Nair S, Song Y, Meghji S, et al. Surface-associated proteins from Staphylococcus aureus demonstrate potent bone resorbing activity. J Bone Miner Res 1995; 10:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/23\">",
"      Littlewood-Evans AJ, Hattenberger MR, L&uuml;scher C, et al. Local expression of tumor necrosis factor alpha in an experimental model of acute osteomyelitis in rats. Infect Immun 1997; 65:3438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/24\">",
"      Schlievert PM. Role of superantigens in human disease. J Infect Dis 1993; 167:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/25\">",
"      De Boeck H. Osteomyelitis and septic arthritis in children. Acta Orthop Belg 2005; 71:505.",
"     </a>",
"    </li>",
"    <li>",
"     Morrissey RT. Bone and Joint Infections. In: Lovell and Winter's Pediatric Ortopaedics, 3rd ed, Morrissey RT (Ed), Lippincott, Philadelphia 1990. p.539.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39269/abstract/27\">",
"      Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am 2005; 19:765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7660 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39269=[""].join("\n");
var outline_f38_22_39269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18562386\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bacterial adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Proteolytic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Resistance to host defense",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differences by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18562386\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7660\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7660|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/2/18468\" title=\"picture 1\">",
"      Acute osteomyelitis light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/61/15315\" title=\"picture 2\">",
"      Early repair in osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/59/29619\" title=\"picture 3\">",
"      Chronic osteomyelitis light microscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/538?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10646?source=related_link\">",
"      Treatment and prevention of osteomyelitis following trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_22_39270="Growth hormone insensitivity syndromes";
var content_f38_22_39270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth hormone insensitivity syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39270/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39270/contributors\">",
"     Alan D Rogol, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39270/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39270/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39270/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39270/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/22/39270/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12573222\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone insensitivity (GHI) is a group of inherited disorders in which there is a reduction in or absence of the biological effects of growth hormone (GH) despite normal or above normal production and secretion of GH. These disorders are characterized by growth failure and normal or increased circulating levels of GH, in contrast to GH deficiency. In addition, most affected individuals also have low circulating levels of the GH binding protein (GHBP, which is equivalent to the shed extracellular binding domain of the GH receptor) and is a commercially available clinical test reflecting the number of GH receptors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classic model of GHI is in patients with Laron syndrome, caused by mutations in the GH receptor gene. However, subsequent experience has shown that there is a spectrum of GHI, caused by a variety of defects along the GH&ndash;IGF-I axis (",
"    <a class=\"graphic graphic_figure graphicRef80626 \" href=\"mobipreview.htm?37/42/38575\">",
"     figure 1",
"    </a>",
"    ). These disorders will be discussed in this topic review.",
"   </p>",
"   <p>",
"    A growing body of literature suggests that some patients with idiopathic short stature often have a component of GH resistance, which may call for alternative treatment approaches such as adjusting GH doses based on IGF-I levels. These considerations are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18248?source=see_link\">",
"     \"Growth hormone treatment for idiopathic short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12573712\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GHI can be caused by loss-of-function mutations in the GH receptor gene or in its downstream mediators, the most important of which is insulin-like growth factor I (IGF-I). These syndromes are characterized by normal or elevated levels of GH and low levels of IGF-I (except for IGF-I receptor mutations, in which IGF-I levels are normal or high) (",
"    <a class=\"graphic graphic_table graphicRef62441 \" href=\"mobipreview.htm?39/31/40444\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12574092\">",
"    <span class=\"h2\">",
"     Growth hormone receptor mutations (Laron syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary GHI, also known as Laron syndrome (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/262500\">",
"     MIM #262500",
"    </a>",
"    ), is characterized by severe postnatal growth failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/1\">",
"     1",
"    </a>",
"    ]. It is caused by homozygous or compound heterozygous mutations in the GH receptor gene; a variety of mutations have been identified, most of which affect the extracellular GH binding region of the receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with homozygous loss-of-function mutations in the GH receptor gene have severe growth failure, with a mean adult height in one report of 119 cm (47 inches) in females, and 124 cm (49 inches) in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/5\">",
"     5",
"    </a>",
"    ]. However, there is wide variability in adult height, ranging in another series from -2.2 to -10.4 standard deviation score (SDS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/6\">",
"     6",
"    </a>",
"    ]. The variation in adult height appears to be caused by variable activation of the GH axis, as reflected by IGF-I and IGFBP-3 levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/7\">",
"     7",
"    </a>",
"    ]. Adult height does not correlate with genotype or with measures of height in family members.",
"   </p>",
"   <p>",
"    Other clinical features of Laron syndrome include small head circumference, characteristic facies with saddle nose and prominent forehead, delayed skeletal maturation, small genitalia and testes, short limb length compared to trunk length, and abnormal body composition, with osteopenia and obesity (",
"    <a class=\"graphic graphic_picture graphicRef80534 \" href=\"mobipreview.htm?13/42/13985\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70163 \" href=\"mobipreview.htm?43/3/44091\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Intellectual development is normal or only modestly impaired. Unlike patients with IGF-I deficiency (described below), there is minimal disturbance of prenatal growth.",
"   </p>",
"   <p>",
"    Patients with Laron syndrome also have metabolic abnormalities including hyperlipidemia and episodes of hypoglycemia, especially during infancy. Data are conflicting on the risk of insulin resistance, which in initial studies was variably present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/9\">",
"     9",
"    </a>",
"    ]. Historically, these individuals were considered at risk for obesity and insulin resistance if untreated with IGF-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/10\">",
"     10",
"    </a>",
"    ]. However, in a later report, patients with Laron syndrome had substantially less insulin resistance and lower rates of diabetes than their relatives without Laron syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moreover, individuals with Laron syndrome appear to have much lower cancer rates than in healthy controls. Experimental evidence from animal models and in vitro studies suggest that the low levels of IGF-I in Laron syndrome are responsible for the reduced susceptibility to cancer and for increased longevity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12574106\">",
"    <span class=\"h2\">",
"     Post-GH receptor mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to GH receptor gene mutations, GHI can occur through mutations in the post-GH receptor signaling pathway. A number of mechanisms have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4965236\">",
"    <span class=\"h3\">",
"     GH receptor signal transduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patients have been described with a GHI syndrome caused by a homozygous missense mutation in the gene encoding STAT5b (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/245590\">",
"     MIM #245590",
"    </a>",
"    ), which is essential for normal signaling of the GH receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The patients have severe postnatal growth failure and immune dysregulation, which is probably because STAT5b also serves as an intermediate in signal transduction and is triggered by various immune ligands, such as IL2, IL4, and CSF1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12574578\">",
"    <span class=\"h3\">",
"     IGF-I gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the gene encoding IGF-I cause a unique syndrome of GHI (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/608747\">",
"     MIM #608747",
"    </a>",
"    ). Complete absence of IGF-I is probably lethal in humans, but individuals have been described with deletions in the IGF-I gene causing partial loss of function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike patients with GH receptor mutations (Laron syndrome), patients with IGF-I gene mutations have prenatal growth failure, microcephaly, significant neurocognitive deficits, sensorineural hearing loss, and normal levels of IGFBP-3. These observations confirm that IGF-I has an important role in fetal growth, as well as brain development, whereas the role of GH during fetal development is less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12574660\">",
"    <span class=\"h3\">",
"     Defective stabilization of circulating IGF-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other patients have a GHI syndrome mediated by deficiency of acid labile subunit (ALS) (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/601489\">",
"     MIM +601489",
"    </a>",
"    ), which is important for the stabilization of the IGF-IGFBP-3 complex, forming a three-part (ternary) complex in the circulation. These patients usually have delayed onset of puberty and slow pubertal progression, but only minimal slowing of linear growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. They have increased plasma levels of GH, normal levels of GH-binding protein (the extracellular portion of the GH receptor), and very low levels of IGF-I and IGFBP-3, which remain low after administration of recombinant GH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12574608\">",
"    <span class=\"h2\">",
"     IGF-I receptor mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the gene encoding the receptor for IGF-I have been reported in infants presenting with pre- and postnatal growth failure (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/270450\">",
"     MIM #270450",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. These mutations are thought to result in partial loss of function of the IGF-I receptor, and the phenotype is variable, with normal or only mildly abnormal cognitive development. Unlike the other GHI syndromes, circulating levels of IGF-I are normal or elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12574025\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laron syndrome, characterized by severe GHI, has been reported in several hundred patients worldwide, the majority of whom have ancestry from the Mediterranean, Middle East, or South Asian regions, including a large cohort living in Ecuador [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/7\">",
"     7",
"    </a>",
"    ]. A history of consanguinity is common, consistent with autosomal recessive pattern of inheritance. The other causes of GHI have been reported in few patients, so the epidemiology and geographical distribution is not clear. However, familial aggregation and a family history of consanguinity are still common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12573705\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a child with short stature requires distinguishing between children with common nonpathological causes such as constitutional delay of growth or familial short stature, those with a non-endocrine cause of growth failure (eg, Crohn&rsquo;s disease), and those with an endocrine cause of short stature who might benefit from hormonal treatment. The general approach to this assessment is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GHI should be suspected in patients with severe growth failure, normal or increased circulating levels of GH, and low IGF-I and IGFBP-3 levels. However, interpretation of these tests requires caution:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the GH level is normal or high, it should be repeated one or more times before concluding that the patient has a GHI syndrome. Normal GH levels are also typical of patients with idiopathic short stature, so this finding is not suspicious for GHI unless the patient also has severe growth failure (height &lt;2.5 SD below the mean).",
"     </li>",
"     <li>",
"      In young children (&lt;3 years old), relatively low levels of IGF-I are the norm, so this finding is not diagnostic of GHI in this age group. Other causes of low IGF-I levels include poor nutritional status, hypothyroidism, and renal failure. Levels of IGFBP-3 may be more informative because it is less likely to vary with age, nutritional status, and chronic illness. In normal children, IGF-I levels rise two- to four-fold during puberty, following a similar rise in GH levels. IGF-I and GH reach maximal levels around the time of peak height velocity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/26\">",
"       26",
"      </a>",
"      ]. IGFBP-3 is low in the GHI syndromes, except for patients with an IGF-I gene mutation, who can be distinguished by severe prenatal growth failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=see_link&amp;anchor=H10#H10\">",
"       \"Diagnosis of growth hormone deficiency in children\", section on 'IGF-I and IGFBP-3'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children with Laron syndrome due to a mutation in the portion of the GH receptor gene encoding the extracellular binding domain, serum levels of GH binding protein (GHBP) will be quite low, signifying a deficiency of GH binding ability to its receptor. Testing for GHBP is commercially available.",
"   </p>",
"   <p>",
"    An IGF-I generation test can be used to further evaluate responsiveness to GH. This consists of a brief trial of growth hormone administration for about one week. In patients with GHI, the low IGF-I will not rise after exogenous administration of growth hormone for four to nine days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the protocols for performing this test have not been standardized, the levels of IGF-I achieved are quite variable, and it may be difficult to obtain the GH required for this short course of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/27\">",
"     27",
"    </a>",
"    ]. Therefore, this is not used routinely to evaluate patients with suspected GHI. Nonetheless, this test can be helpful in clarifying the diagnosis, in conjunction with the clinical and other laboratory findings described above.",
"   </p>",
"   <p>",
"    If GHI is confirmed, most patients will have a mutation in the growth hormone receptor gene. Specific testing for GH receptor mutations is available through some clinical laboratories, which are listed on the",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/3212?db=genetests\">",
"     GeneTests website",
"    </a>",
"    . GH stimulation testing usually is not necessary, because the basal levels of GH are normal or high in patients with GHI, distinguishing them from individuals with GH deficiency. If GH stimulation testing is performed, the GH response to stimulation is usually robust.",
"   </p>",
"   <p>",
"    Patients with post-GH receptor defects have distinct clinical and biochemical patterns (",
"    <a class=\"graphic graphic_table graphicRef62441 \" href=\"mobipreview.htm?39/31/40444\">",
"     table 1",
"    </a>",
"    ). In patients with marked prenatal growth failure, an IGF-I gene mutation should be considered. Like patients with GH receptor mutations, these patients will have normal or increased levels of GH and low IGF-I levels. Unlike patients with GH receptor mutations, IGFBP-3 is elevated. (See",
"    <a class=\"local\" href=\"#H12574578\">",
"     'IGF-I gene mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Notably, most short patients with normal GH levels do",
"    <strong>",
"     not",
"    </strong>",
"    have one of these GHI syndromes and are classified as having idiopathic short stature rather than GHI. However, lesser degrees of GH resistance may play a role in idiopathic short stature (",
"    <a class=\"graphic graphic_figure graphicRef80626 \" href=\"mobipreview.htm?37/42/38575\">",
"     figure 1",
"    </a>",
"    ). Most of these patients with idiopathic short stature are not eligible for treatment with recombinant IGF-I based on current treatment recommendations, which are described below. Such patients may respond to GH therapy, but they may require adjustment of the GH dose to achieve therapeutic IGF-I levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18248?source=see_link&amp;anchor=H12#H12\">",
"     \"Growth hormone treatment for idiopathic short stature\", section on 'Dose adjustment for IGF-I levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12573649\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with GHI are not responsive to treatment with GH, but usually respond to treatment with IGF-I. The growth response of a patient with GHI treated with IGF-I is substantially less than that of a GH-deficient patient treated with GH.",
"   </p>",
"   <p>",
"    Patients with mutations of the IGF-I receptor have elevated IGF-I levels and would not be expected to respond to IGF-I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12573574\">",
"    <span class=\"h2\">",
"     Recombinant IGF-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant human IGF-I (Mecasermin, Increlex&trade;) is an effective treatment for children with severe primary IGF-I deficiency, whether due to mutations in the GH receptor, post-GH receptor signaling pathway, or IGF-I gene. Accepted indications for treatment are height and basal IGF-I standard deviation scores both &le;-3.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/28\">",
"     28",
"    </a>",
"    ]. It may also be used in children with primary GH deficiency due to a GH gene deletion who have developed neutralizing antibodies during treatment with GH, causing an acquired GH insensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of IGF-I treatment on children with severe primary IGF-I deficiency were examined in an open-label study of 76 children treated for up to 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/30\">",
"     30",
"    </a>",
"    ]. Height velocity increased from 2.8",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    at baseline to a mean of 8",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    during the first year of treatment. Height velocity remained above baseline for up to eight years. However, this growth response was less than that typically attained in GH-deficient children receiving GH therapy. This treatment also results in rapid catch-up growth of head circumference and normalization of metabolic abnormalities such as hyperlipidemia and insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IGF-I has also been effectively used for patients GHI caused by mutations in the IGF-I gene, resulting in increased linear growth and beneficial effects on body composition, including increased bone mineral density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12574578\">",
"     'IGF-I gene mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recombinant IGF-I should be administered as subcutaneous injection twice daily shortly before or after a meal (&plusmn;20 minutes) to avoid hypoglycemia, particularly in younger children and in those with hypoglycemic episodes prior to the initiation of treatment. In the study cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/30\">",
"     30",
"    </a>",
"    ], hypoglycemia occurred in 40 percent of subjects, was severe in 9 percent, and 5 percent of the subjects had at least one hypoglycemic seizure. Other side effects included adenotonsillar hypertrophy (22 percent) and intracranial hypertension (4 percent). Another reported side effect is idiopathic intracranial hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/33\">",
"     33",
"    </a>",
"    ], which also has been reported during GH treatment of children with GHD.",
"   </p>",
"   <p>",
"    A few allergic reactions to mecasermin, including anaphylaxis, have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. One such patient had negative skin testing to the drug and was treated with a desensitization protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39270/abstract/35\">",
"     35",
"    </a>",
"    ]. Despite these precautions, this patient developed recurrent allergic reactions after three additional weeks of treatment with mecasermin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12573401\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth hormone insensitivity (GHI) can be caused by loss-of-function mutations in the growth hormone (GH) receptor, or in its downstream mediators, including insulin-like growth factor I (IGF-I). These rare syndromes are characterized by normal or elevated levels of GH and low levels of IGF-I (except for IGF-I receptor mutations, in which IGF-I levels are normal) (",
"      <a class=\"graphic graphic_table graphicRef62441 \" href=\"mobipreview.htm?39/31/40444\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12573712\">",
"       'Pathophysiology and clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary GHI syndrome, or classic Laron syndrome, is caused by mutations in the GH receptor. Affected patients have severe postnatal growth failure, characteristic facies, and metabolic abnormalities (",
"      <a class=\"graphic graphic_picture graphicRef80534 \" href=\"mobipreview.htm?13/42/13985\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70163 \" href=\"mobipreview.htm?43/3/44091\">",
"       table 2",
"      </a>",
"      ). Most cases are from populations with Mediterranean or Middle Eastern ancestry, and a family history of consanguinity is common. (See",
"      <a class=\"local\" href=\"#H12574092\">",
"       'Growth hormone receptor mutations (Laron syndrome)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary GHI should be suspected in patients with severe growth failure, normal or increased circulating levels of GH, and low IGF-I and IGFBP-3 levels. The diagnosis can be confirmed if a brief trial of GH therapy fails to cause a rise of serum IGF-I, or through genetic testing. (See",
"      <a class=\"local\" href=\"#H12573705\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with marked prenatal growth failure, an IGF-I gene mutation should be considered. Like patients with GH receptor mutations, these patients will have normal or increased levels of GH and low IGF-I levels. Unlike patients with GH receptor mutations, the plasma IGFBP-3 level is elevated (",
"      <a class=\"graphic graphic_table graphicRef62441 \" href=\"mobipreview.htm?39/31/40444\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12574578\">",
"       'IGF-I gene mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with severe GHI (defined as height and basal IGF-I standard deviation scores &le;-3.0, with normal or elevated levels of GH) be treated with IGF-I (mecasermin) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Hypoglycemia is a common side effect of recombinant IGF-I, particularly in younger children. GH therapy is ineffective for such patients. (See",
"      <a class=\"local\" href=\"#H12573649\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most short patients with normal GH levels do not have one of these GHI syndromes, and are classified as having idiopathic short stature rather than GHI. However, lesser degrees of GH resistance may play a role in idiopathic short stature (",
"      <a class=\"graphic graphic_figure graphicRef80626 \" href=\"mobipreview.htm?37/42/38575\">",
"       figure 1",
"      </a>",
"      ). Most of these patients with idiopathic short stature are not eligible for treatment with recombinant IGF-I. (See",
"      <a class=\"local\" href=\"#H12573705\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18248?source=see_link&amp;anchor=H12#H12\">",
"       \"Growth hormone treatment for idiopathic short stature\", section on 'Dose adjustment for IGF-I levels'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/1\">",
"      Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism? Isr J Med Sci 1966; 2:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/2\">",
"      Fang P, Girgis R, Little BM, et al. Growth hormone (GH) insensitivity and insulin-like growth factor-I deficiency in Inuit subjects and an Ecuadorian cohort: functional studies of two codon 180 GH receptor gene mutations. J Clin Endocrinol Metab 2008; 93:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/3\">",
"      Arman A, Ozon A, Isguven PS, et al. Novel splice site mutation in the growth hormone receptor gene in Turkish patients with Laron-type dwarfism. J Pediatr Endocrinol Metab 2008; 21:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/4\">",
"      Goddard AD, Covello R, Luoh SM, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med 1995; 333:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/5\">",
"      Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993; 68:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/6\">",
"      Woods KA, Dastot F, Preece MA, et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997; 82:3529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/7\">",
"      Rosenbloom AL, Guevara-Aguirre J. Lessons from the genetics of laron syndrome. Trends Endocrinol Metab 1998; 9:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/8\">",
"      Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/9\">",
"      Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004; 89:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/10\">",
"      Laron Z. Consequences of not treating children with laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab 2001; 14 Suppl 5:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/11\">",
"      Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3:70ra13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/12\">",
"      Ikeno Y, Hubbard GB, Lee S, et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 2009; 64:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/13\">",
"      Kofoed EM, Hwa V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003; 349:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/14\">",
"      Chia DJ, Subbian E, Buck TM, et al. Aberrant folding of a mutant Stat5b causes growth hormone insensitivity and proteasomal dysfunction. J Biol Chem 2006; 281:6552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/15\">",
"      Hwa V, Camacho-H&uuml;bner C, Little BM, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res 2007; 68:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/16\">",
"      Rosenfeld RG, Hwa V. The growth hormone cascade and its role in mammalian growth. Horm Res 2009; 71 Suppl 2:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/17\">",
"      Cohen AC, Nadeau KC, Tu W, et al. Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol 2006; 177:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/18\">",
"      Woods KA, Camacho-H&uuml;bner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996; 335:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/19\">",
"      Bonapace G, Concolino D, Formicola S, Strisciuglio P. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 2003; 40:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/20\">",
"      Domen&eacute; HM, Bengolea SV, Mart&iacute;nez AS, et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004; 350:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/21\">",
"      Domen&eacute; HM, Hwa V, Argente J, et al. Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009; 72:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/22\">",
"      Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003; 349:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/23\">",
"      Kiess W, Kratzsch J, Keller E, et al. Clinical examples of disturbed IGF signaling: intrauterine and postnatal growth retardation due to mutations of the insulin-like growth factor I receptor (IGF-IR) gene. Rev Endocr Metab Disord 2005; 6:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/24\">",
"      Kawashima Y, Higaki K, Fukushima T, et al. Novel missense mutation in the IGF-I receptor L2 domain results in intrauterine and postnatal growth retardation. Clin Endocrinol (Oxf) 2012; 77:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/25\">",
"      Gannag&eacute;-Yared MH, Klammt J, Chouery E, et al. Homozygous mutation of the IGF1 receptor gene in a patient with severe pre- and postnatal growth failure and congenital malformations. Eur J Endocrinol 2013; 168:K1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/26\">",
"      Martha PM Jr, Rogol AD, Veldhuis JD, et al. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab 1989; 69:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/27\">",
"      Savage MO, Burren CP, Rosenfeld RG. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf) 2010; 72:721.",
"     </a>",
"    </li>",
"    <li>",
"     Increlex prescribing information, Revised September 2008. Available at:  file://www.increlex.com/pdf/Full_Prescribing_Information.pdf (Accessed on October 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/29\">",
"      Collett-Solberg PF, Misra M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008; 93:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/30\">",
"      Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/31\">",
"      Woods KA, Camacho-H&uuml;bner C, Bergman RN, et al. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000; 85:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/32\">",
"      Concolino D, Muzzi G, Sestito S, et al. Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation. Eur J Pediatr 2010; 169:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/33\">",
"      Ko MW, Liu GT. Pediatric idiopathic intracranial hypertension (pseudotumor cerebri). Horm Res Paediatr 2010; 74:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/34\">",
"      Torjusen E, Calderon J, Rivkees SA. Anaphylactic reaction to recombinant insulin-like growth factor-I. J Pediatr Endocrinol Metab 2008; 21:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39270/abstract/35\">",
"      Metz KA, Assa'ad A, Lierl MB, Backeljauw P. Allergic reaction to mecasermin. Ann Allergy Asthma Immunol 2009; 103:82.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15796 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-109.230.63.219-AC07DF7577-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39270=[""].join("\n");
var outline_f38_22_39270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12573401\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12573222\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12573712\">",
"      PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12574092\">",
"      Growth hormone receptor mutations (Laron syndrome)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12574106\">",
"      Post-GH receptor mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4965236\">",
"      - GH receptor signal transduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12574578\">",
"      - IGF-I gene mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12574660\">",
"      - Defective stabilization of circulating IGF-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12574608\">",
"      IGF-I receptor mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12574025\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12573705\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12573649\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12573574\">",
"      Recombinant IGF-I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12573401\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15796|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/42/38575\" title=\"figure 1\">",
"      Spectrum growth hormone sensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15796|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/42/13985\" title=\"picture 1\">",
"      Laron syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/31/40444\" title=\"table 1\">",
"      Growth hormone insensitivity syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/3/44091\" title=\"table 2\">",
"      Clinical features of Laron syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18248?source=related_link\">",
"      Growth hormone treatment for idiopathic short stature",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_22_39271="Treatment and prevention of Bordetella pertussis infection in adolescents and adults";
var content_f38_22_39271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39271/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39271/contributors\">",
"     Paul Cornia, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39271/contributors\">",
"     Benjamin Lipsky, MD, FACP, FIDSA, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39271/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39271/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39271/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39271/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/22/39271/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12882590\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pertussis, also known as &ldquo;whooping cough,&rdquo; is a highly contagious, acute respiratory illness caused by Bordetella pertussis. In the pre-vaccine era, the disease predominantly affected children &lt;10 years of age and usually manifested as a prolonged cough illness with one or more of the classical symptoms, including inspiratory whoop, paroxysmal cough, and post-tussive emesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the introduction of pertussis vaccines, the epidemiology of reported pertussis infections has changed; in the United States in the 1990s, more than one-half of cases occurred in adolescents and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/2\">",
"     2",
"    </a>",
"    ]. Infected adolescents and adults serve can serve as a reservoir for infection of infants and children in whom serious morbidity and mortality may occur. Symptoms and signs in adolescents and adults are often non-specific and the diagnosis may not be considered.",
"   </p>",
"   <p>",
"    Issues related to treatment and prevention of pertussis will be reviewed here. The pathogenesis, epidemiology, clinical manifestations, and diagnosis of this infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/27/20918?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25833?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16248?source=see_link\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882597\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many individuals clear the infection without antibiotic treatment within three to four weeks (80 to 90 percent in some series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/3\">",
"     3",
"    </a>",
"    ]. During the early (catarrhal) phase of pertussis, antibiotic treatment may decrease the duration and severity of cough, but, among adolescents and adults, the diagnosis is rarely established during this phase. Antibiotic treatment later in the course of disease probably does not affect the course of symptoms, but may be useful to reduce the spread of the infection.",
"   </p>",
"   <p>",
"    The United States Centers for Disease Control and Prevention (CDC) has published a comprehensive set of recommendations for the treatment and post-exposure prophylaxis of pertussis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, antibiotic therapy is warranted for patients with duration of symptoms &le;2 weeks; it may also be given for patients with persistent symptoms for up to four weeks. Among healthcare workers, pregnant women, and individuals working with infants, antibiotic therapy is appropriate for individuals with persistent symptoms for up to eight weeks.",
"   </p>",
"   <p>",
"    Given the highly contagious nature of the disease and the delay in availability of culture test results (which may take 7 to 10 days), we are in agreement with the CDC, which advocates the same thresholds for initiating testing and treatment: in the setting of sufficient clinical suspicion for pertussis, empirical antibiotic therapy should be initiated at the time diagnostic testing is performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antibiotic regimens for treatment and post-exposure prophylaxis are identical. (See",
"    <a class=\"local\" href=\"#H12882709\">",
"     'Postexposure prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882611\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrolides are highly effective at eradicating B. pertussis from the nasopharynx [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. We are in agreement with the CDC treatment recommendations, which consist of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    for five days (500 mg day one, followed by 250 mg days two through five) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (500 mg twice daily for seven days) (",
"    <a class=\"graphic graphic_table graphicRef75339 \" href=\"mobipreview.htm?24/3/24636\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/4\">",
"     4",
"    </a>",
"    ]. For adults who cannot tolerate macrolide antibiotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX; one double strength tablet twice daily for 14 days) is an acceptable alternative treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    are more stable than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    at gastric acid pH levels, allowing increased oral bioavailability and less frequent dosing. Erythromycin requires four times daily dosing and has associated gastrointestinal toxicity (abdominal cramping, nausea, vomiting, and diarrhea).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    does not appear to affect hepatic enzymes (eg, cytochrome P450 system), but is contraindicated for persons with prior history of cholestatic hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    inhibit the cytochrome P450 enzyme system; concomitant use of a drug metabolized by the cytochrome P450 system may result in increased drug levels of that drug and resultant toxicity, including QT interval prolongation and sudden cardiac death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro susceptibility of B. pertussis to the fluoroquinolone antimicrobial class has been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/8-11\">",
"     8-11",
"    </a>",
"    ], although there are no reported clinical data to support its use.",
"   </p>",
"   <p>",
"    Routine antimicrobial susceptibility testing is not needed for B. pertussis since macrolide resistance is relatively uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/4\">",
"     4",
"    </a>",
"    ]. However, in unusual cases of failure with macrolide therapy, clinical isolates of B. pertussis may be tested for macrolide susceptibility using standard methodology, including E-test and disk diffusion assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to treatment following exposure are discussed below. (See",
"    <a class=\"local\" href=\"#H12882709\">",
"     'Postexposure prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882653\">",
"    <span class=\"h2\">",
"     Cough management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven effective therapy for symptomatic treatment of severe cough due to pertussis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/13\">",
"     13",
"    </a>",
"    ]. The cough is likely related to reduction in respiratory ciliated cells due to pertussis toxins, leading to trickle of secretions from the nasopharynx into the larynx. Symptomatic relief requires regrowth of these cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882660\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial vaccines developed following the isolation of the B. pertussis organism in the early 1900s contained killed whole cell B. pertussis organisms. Subsequently, acellular pertussis vaccines containing purified components of the organism were developed; these have a more favorable side effect profile. In countries with effective implementation of universal childhood vaccination programs, dramatic reductions in the incidence of pertussis have been observed.",
"   </p>",
"   <p>",
"    Other measures for the prevention and control of pertussis include home or hospital room isolation of known or suspected cases, and post-exposure prophylactic antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882667\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood vaccination is highly effective in preventing pertussis. The efficacy of the whole cell vaccine in preventing serious infection in children is 70 to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The DTP vaccine consists of the whole cell pertussis vaccine combined with diphtheria and tetanus toxoids. The whole cell pertussis vaccine is no longer available in the United States, but is still used in other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acellular vaccines were developed and first licensed for use in the United States in 1991 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Routine childhood vaccination in the United States is performed with the DTaP vaccine (acellular pertussis vaccine combined with tetanus and diphtheria toxoids) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Booster vaccination for adolescents and adults is performed with Tdap (acellular pertussis vaccine combined with tetanus toxoid and reduced diphtheria toxoid; the lower case &ldquo;d&rdquo; and &ldquo;p&rdquo; indicate lower quantities of diphtheria and pertussis antigen in the adult formulation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/19\">",
"     19",
"    </a>",
"    ]. There are two formulations: Boostrix&trade; and ADACEL&trade; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5842133\">",
"    <span class=\"h3\">",
"     Tdap booster",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882674\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and immunogenicity of acellular pertussis vaccines in adolescents and adults have been demonstrated in randomized, placebo-controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/22-29\">",
"     22-29",
"    </a>",
"    ]. In the largest randomized control trial, which included 4480 adolescents and adults (aged 11 through 64 years), Tdap elicited a robust immune response with an overall safety profile similar to that of Td [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of acellular pertussis vaccine (without tetanus diphtheria vaccine [Td]) among adolescents and adults was also demonstrated in a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/29\">",
"     29",
"    </a>",
"    ]. Among healthy individuals between the ages of 15 and 65 years who received either acellular pertussis or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    , the vaccine efficacy was 92 percent (95% CI, 32 to 99 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882681\">",
"    <span class=\"h4\">",
"     General use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents aged 11 to 18 years should receive a single booster immunization with Tdap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/19\">",
"     19",
"    </a>",
"    ]. The use of Tdap for adolescents is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34233?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adults aged 19 to 64 years should receive a single booster administration with Tdap, as recommended by the United States Advisory Committee on Immunization Practices (ACIP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, adults aged 65 years and older who have not previously received Tdap should receive a single booster administration with Tdap; this recommendation was updated by ACIP in June 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This is particularly important for adults aged 65 and older who have close contact with infants aged younger than one year (such as grandparents, child care providers, and healthcare providers). Other adults for whom vaccination is particularly important include those with obesity and preexisting asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Either vaccine formulation, Boostrix or Adacel, can be administered to a person 65 years or older; when feasible Boostrix should be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/31\">",
"     31",
"    </a>",
"    ]. However, providers should not miss an opportunity to vaccinate an individual aged 65 years and older, so should administer the Tdap vaccine that is available. Prior to the ACIP recommendations issued in June 2012, the FDA had approved Boostrix for individuals aged 10 years and older, and Adacel for individuals between 11 and 64 years of age. Subsequent data has indicated that immunization of adults aged &ge;65 years with Tdap to reduce the risk of pertussis in the elderly and their contacts should not have untoward safety consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tdap should be administered regardless of the interval since the last dose of Td. This represents a change from previous ACIP guidelines, which recommended that Tdap be given a minimum of two years after the last dose of Td in most cases.",
"   </p>",
"   <p>",
"    Subsequent tetanus booster doses, in the form of Td, should be given at 10-year intervals throughout adulthood. Thus far, safety and efficacy data for administration of Tdap at 10-year intervals appears promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/34\">",
"     34",
"    </a>",
"    ]; once more data is available, it is possible that Tdap may replace Td as the routine booster immunization given at 10-year intervals.",
"   </p>",
"   <p>",
"    Booster vaccination is appropriate even for patients who have had a recent clinical episode of pertussis.",
"   </p>",
"   <p>",
"    Vaccination in pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882688\">",
"    <span class=\"h4\">",
"     Healthcare personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare personnel (HCP) are at risk for exposure to pertussis, as well as exposing vulnerable patients when they are infectious. Numerous nosocomial outbreaks of pertussis have been attributed to HCP exposure, with considerable associated morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/20,35-37\">",
"     20,35-37",
"    </a>",
"    ]. Tdap vaccination in adult healthcare workers is effective in controlling nosocomial outbreaks of pertussis and less costly than a hospital outbreak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/20,35\">",
"     20,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unvaccinated HCPs who have direct patient contact should receive a single Tdap vaccination as soon as feasible, regardless of the time since the last Td dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/38\">",
"     38",
"    </a>",
"    ]. After receipt of Tdap, HCPs should receive routine booster immunization against tetanus and diphtheria as outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13322?source=see_link\">",
"     \"Immunizations for healthcare providers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882702\">",
"    <span class=\"h3\">",
"     International strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international collaboration, the Global Pertussis Initiative (GPI), was established in 2001. This group has assessed various vaccination strategies in addition to routine childhood immunizations, including universal adolescent, adult, and preschool booster vaccination as well as selective vaccination of healthcare workers, child care workers, new mothers, and close contacts of newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/39\">",
"     39",
"    </a>",
"    ]. Given the global variability in pertussis epidemiology and healthcare resources, they could not recommend a uniform set of guidelines for all countries but offered the following strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      North America &mdash; Adolescent and adult vaccination to develop lifelong immunity to pertussis. This has been implemented by the ACIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Europe &mdash; Improve adherence to current vaccination recommendations; add a universal preschool vaccination or an adolescent booster dose in all countries; selectively vaccinate healthcare workers.",
"     </li>",
"     <li>",
"      Australia &mdash; Selectively vaccinate healthcare workers and new mothers, family, and close contacts of newborns (adolescent vaccination already performed).",
"     </li>",
"     <li>",
"      Japan &mdash; Begin universal preschool (fourth dose) and adolescent vaccination.",
"     </li>",
"     <li>",
"      Argentina &mdash; Begin universal adolescent vaccination (preschool vaccination already performed).",
"     </li>",
"     <li>",
"      Brazil &mdash; Given the current focus on control of malaria and tuberculosis, expanding pertussis vaccine programs will likely not occur without more data, particularly on cost-effectiveness.",
"     </li>",
"     <li>",
"      For all countries &mdash; Reinforce",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      improve current infant and toddler vaccination, particularly in impoverished populations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882709\">",
"    <span class=\"h2\">",
"     Postexposure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure antibiotic prophylaxis is warranted for individuals with close contact to a person with pertussis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/4\">",
"     4",
"    </a>",
"    ]. A close contact is defined as a person who has had face-to-face exposure within three feet of a symptomatic patient. Individuals with direct contact with respiratory, nasal or oral secretions may also be considered close contacts. The threshold to administer postexposure antibiotics may be lower in certain groups with high risk for morbidity and mortality including infants and individuals with chronic lung disease and immunodeficiency. The antibiotic regimens for postexposure prophylaxis are identical to those used for the treatment of pertussis (",
"    <a class=\"graphic graphic_table graphicRef75339 \" href=\"mobipreview.htm?24/3/24636\">",
"     table 1",
"    </a>",
"    ). Administration of postexposure therapy to asymptomatic contacts within 21 days of onset of cough in the index patient can prevent symptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposed individuals, especially those with an incomplete vaccination history, should be closely observed for symptoms and signs of pertussis for three weeks after contact. Postexposure immunization, either passive with immunoglobulin or active with pertussis vaccine, does",
"    <strong>",
"     not",
"    </strong>",
"    protect contacts from infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14100668\">",
"    <span class=\"h2\">",
"     Other control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-exposure immunization does not protect contacts from infection.",
"   </p>",
"   <p>",
"    Patients with B. pertussis infection should avoid contact with young children and infants, particularly unimmunized children, until they have completed at least five days of appropriate antibiotic therapy. Similarly, infected individuals working in schools, daycare centers, or healthcare facilities should not return to work until completing at least five days of appropriate antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39271/abstract/5,41\">",
"     5,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=see_link\">",
"       \"Patient information: Tdap vaccine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12882723\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most adolescents and adults clear pertussis infection without antibiotic treatment within three to four weeks. Antibiotic treatment later in the course of disease (when the diagnosis is usually established) probably does not affect the course of symptoms, but may be useful to reduce the spread of the infection. (See",
"      <a class=\"local\" href=\"#H12882597\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the highly contagious nature of pertussis and the delay in availability of culture test results (which may take 7 to 10 days), in the setting of sufficient clinical suspicion for pertussis, initiation of empirical antibiotic therapy may be appropriate depending on the duration of symptoms. (See",
"      <a class=\"local\" href=\"#H12882597\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with duration of symptoms &le;2 weeks, we recommend antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with persistent symptoms for up to four weeks, we suggest antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with persistent symptoms for up to eight weeks, we suggest antibiotic treatment for individuals in the following categories: healthcare workers, pregnant women, and individuals working with infants (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12882597\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimicrobial therapy for treatment of pertussis is outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef75339 \" href=\"mobipreview.htm?24/3/24636\">",
"       table 1",
"      </a>",
"      ). We suggest treatment with",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/azithromycin-drug-information?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/clarithromycin-drug-information?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ); these are better tolerated and have more convenient dosing than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      . For patients who cannot tolerate macrolide antibiotics,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      is an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H12882611\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend booster vaccination with Tdap for adolescents and adults (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Vaccination is particularly important for adults who have close contact with infants aged younger than one year (such as grandparents, child care providers, and healthcare providers). (See",
"      <a class=\"local\" href=\"#H5842133\">",
"       'Tdap booster'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend postexposure prophylaxis for individuals and healthcare personnel in close contact with cases of pertussis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ); the prophylaxis regimen is the same as the treatment regimen (",
"      <a class=\"graphic graphic_table graphicRef75339 \" href=\"mobipreview.htm?24/3/24636\">",
"       table 1",
"      </a>",
"      ). Prior vaccination with Tdap should not be considered sufficiently protective to eliminate need for chemoprophylaxis. (See",
"      <a class=\"local\" href=\"#H12882709\">",
"       'Postexposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with B. pertussis infection should avoid contact with young children and infants until they have completed at least five days of antibiotics. Similarly, patients working in schools, daycare centers, or healthcare facilities should not return to work until after five days of antibiotic treatment. (See",
"      <a class=\"local\" href=\"#H14100668\">",
"       'Other control measures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18284597\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Christopher Ohl, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/1\">",
"      G&uuml;ri D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/3\">",
"      Kwantes W, Joynson DH, Williams WO. Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan. J Hyg (Lond) 1983; 90:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/4\">",
"      Tiwari T, Murphy TV, Moran J, National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/5\">",
"      Bergquist SO, Bernander S, Dahnsj&ouml; H, Sundel&ouml;f B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/6\">",
"      Strle F, Maraspin V. Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr 2002; 114:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/7\">",
"      Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/8\">",
"      Kerr JR, Preston NW. Current pharmacotherapy of pertussis. Expert Opin Pharmacother 2001; 2:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/9\">",
"      Hoppe JE, Dalhoff A, Pfr&uuml;nder D. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1998; 42:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/10\">",
"      Mortensen JE, Rodgers GL. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J Antimicrob Chemother 2000; 45 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/11\">",
"      Felmingham D, Farrell DJ. In vitro activity of telithromycin against Gram-negative bacterial pathogens. J Infect 2006; 52:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/12\">",
"      Hoppe JE. Susceptibility testing of Bordetella pertussis. J Clin Microbiol 1998; 36:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/13\">",
"      Bettiol S, Thompson MJ, Roberts NW, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2010; :CD003257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/14\">",
"      Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Vaccines and Immunizations. Pertussis. Epidemiology and Prevention of Vaccine-Preventable Diseases, The Pink Book: Course Textbooks, 12th ed, 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/pert.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/16\">",
"      Singh M, Lingappan K. Whooping cough: the current scene. Chest 2006; 130:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/17\">",
"      Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/18\">",
"      Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use--supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/19\">",
"      Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/20\">",
"      Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/21\">",
"      Adacel and Boostrix: Tdap vaccines for adolescents and adults. Med Lett Drugs Ther 2006; 48:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/22\">",
"      Keitel WA, Muenz LR, Decker MD, et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 1999; 180:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/23\">",
"      Halperin SA, Smith B, Russell M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000; 18:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/24\">",
"      Rothstein EP, Anderson EL, Decker MD, et al. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates. Vaccine 1999; 17:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/25\">",
"      Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000; 18:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/26\">",
"      Tran Minh NN, He Q, Edelman K, et al. Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults. Vaccine 2000; 18:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/27\">",
"      Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000; 19:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/28\">",
"      Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/29\">",
"      Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm?s_cid=mm6001a4_w.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Adults Aged 65 Years and Older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/32\">",
"      Liu BC, McIntyre P, Kaldor JM, et al. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis 2012; 55:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/33\">",
"      France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121:e687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/34\">",
"      Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010; 51:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/35\">",
"      Calugar A, Ortega-S&aacute;nchez IR, Tiwari T, et al. Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 2006; 42:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/36\">",
"      Baggett HC, Duchin JS, Shelton W, et al. Two nosocomial pertussis outbreaks and their associated costs - King County, Washington, 2004. Infect Control Hosp Epidemiol 2007; 28:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/37\">",
"      Flanagan MP. How to manage a pertussis outbreak in your practice. Fam Pract Manag 2005; 12:31.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdph.ca.gov/HealthInfo/discond/Documents/ACIPRecommendationsOnTdapAndPEP.pdf (Accessed on March 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39271/abstract/39\">",
"      Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004; 39:1802.",
"     </a>",
"    </li>",
"    <li>",
"     Pertussis, Parapertussis (Whooping cough). In: Control of Communicable Diseases Manual, 17th ed, Chin J.  (Ed), American Public Health Association, Washington, DC 2000. p.34.",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Pertussis (Whooping Cough). Treatment. file://www.cdc.gov/pertussis/clinical/treatment.html.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8044 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39271=[""].join("\n");
var outline_f38_22_39271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12882723\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12882590\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12882597\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12882611\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12882653\">",
"      Cough management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12882660\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12882667\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5842133\">",
"      - Tdap booster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12882674\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12882681\">",
"      General use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12882688\">",
"      Healthcare personnel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12882702\">",
"      - International strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12882709\">",
"      Postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14100668\">",
"      Other control measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12882723\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18284597\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8044\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8044|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/3/24636\" title=\"table 1\">",
"      Pertussis Rx and prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13322?source=related_link\">",
"      Immunizations for healthcare providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/27/20918?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=related_link\">",
"      Patient information: Tdap vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25833?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_22_39272="ITGCNU pathology";
var content_f38_22_39272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intratubular germ cell neoplasia, unclassified",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A microscopic image of intratubular germ cell neoplasia of unclassified type (ITGCNU) showing large neoplastic germ cells in the seminiferous tubules. Compared to the residual non-neoplastic germ cells, neoplastic germ cells are larger with clear cytoplasm and dark central nuclei, demonstrating so called \"fried egg\" appearance, resembling the seminoma cells. However, different from seminoma cells, the neoplastic cells in ITGCNU are not invasive, since they are confined within the basement membrane of the tubules. Occasional elongated sertoli cells with small nuclei can be seen in the tubules as well.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ximing Yang, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39272=[""].join("\n");
var outline_f38_22_39272=null;
var title_f38_22_39273="Posterior circulation cerebrovascular syndromes";
var content_f38_22_39273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Posterior circulation cerebrovascular syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39273/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39273/contributors\">",
"     Louis R Caplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39273/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39273/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/22/39273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty percent of ischemic events in the brain involve posterior circulation (vertebrobasilar) structures. This topic will review the major clinical syndromes associated with posterior circulation ischemia related to stenosis or occlusion of the large aortic arch, neck, and intracranial arteries. These arteries are the innominate and subclavian arteries in the chest, the vertebral arteries in the neck, and the intracranial vertebral, basilar, and posterior cerebral arteries.",
"   </p>",
"   <p>",
"    The evaluation and management of acute ischemic stroke (including stroke involving the posterior circulation) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCE OF ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of posterior circulation large artery ischemia are atherosclerosis, embolism, and dissection. Dolichoectasia (elongation and tortuosity) of the vertebral and basilar arteries is another occasional cause.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About one-third of posterior circulation strokes are caused by occlusive disease within the large neck and intracranial arteries, which are the vertebral arteries in the neck and the intracranial vertebral, basilar, and posterior cerebral arteries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The proximal portion of the vertebral artery in the neck is the most common location of atherosclerotic occlusive disease within the posterior circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1-5\">",
"       1-5",
"      </a>",
"      ]. Atherosclerosis of the intracranial vertebral arteries and of the basilar artery is also common. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/61/2010?source=see_link\">",
"       \"Intracranial large artery atherosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dissection of the extracranial and intracranial vertebral arteries is another frequent cause of ischemia within the posterior circulation.",
"     </li>",
"     <li>",
"      Unlike the vertebral and basilar arteries, atherosclerosis and dissection of the posterior cerebral arteries is not common. Most infarcts in the posterior cerebral artery territory are due to embolism from the heart, aorta, or vertebral arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SUBCLAVIAN AND INNOMINATE ARTERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherostenotic lesions of the innominate and subclavian arteries do cause arm ischemia and transient ischemic attacks (TIAs) but seldom cause strokes. Because the vertebral arteries in the neck originate from the proximal subclavian arteries, disease of the subclavian or innominate arteries proximal to the vertebral artery origin can cause reduction of vertebral artery flow.",
"   </p>",
"   <p>",
"    In the subclavian steal syndrome, obstruction of the proximal subclavian artery produces a low-pressure system within the ipsilateral vertebral artery and in blood vessels of the ipsilateral upper extremity. Blood from a higher-pressure system, the contralateral vertebral artery and basilar artery, is diverted and flows retrograde downward into the ipsilateral vertebral artery into the arm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/39/36471?source=see_link&amp;anchor=H5#H5\">",
"     \"Subclavian steal syndrome\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/39/36471?source=see_link&amp;anchor=H6#H6\">",
"     \"Subclavian steal syndrome\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most often, subclavian artery disease is detected when patients with coronary or peripheral vascular occlusive disease are referred to ultrasound laboratories for noninvasive testing.",
"   </p>",
"   <p>",
"    Most patients with subclavian artery disease are asymptomatic. The most frequent symptoms of subclavian artery disease relate to the ipsilateral arm and hand. Coolness, weakness, and pain on use of the arm are common.",
"   </p>",
"   <p>",
"    Neurologic symptoms are uncommon unless there is accompanying carotid artery disease. Dizziness is by far the most common neurologic symptom of the subclavian steal syndrome, and usually has a spinning or vertiginous character. Diplopia, decreased vision, oscillopsia, and staggering all occur, but less frequently, often accompanying the dizziness. Attacks are brief and occasionally are brought on by exercising the ischemic arm. However, in most patients exercise of the ischemic limb does not provoke neurologic symptoms or signs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/39/36471?source=see_link&amp;anchor=H5#H5\">",
"     \"Subclavian steal syndrome\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/39/36471?source=see_link&amp;anchor=H6#H6\">",
"     \"Subclavian steal syndrome\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Innominate artery disease is much less common than subclavian artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1,3,6\">",
"     1,3,6",
"    </a>",
"    ]. When the innominate artery becomes stenotic or occluded, signs and symptoms of decreased carotid artery flow may also develop. Ipsilateral monocular visual loss, ipsilateral cerebral hemisphere ischemia in the territories of the anterior and middle cerebral arteries, ipsilateral arm ischemia, and ischemic symptoms referable to the distal portion of the posterior circulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the cerebellum may be due to innominate artery disease.",
"   </p>",
"   <p>",
"    Takayasu's disease and giant cell (temporal) arteritis can cause subclavian and innominate artery occlusive disease. Young women who smoke cigarettes and take oral contraceptives may develop occlusive disease of the aortic arch vessels that mimics Takayasu's disease, except that it is not inflammatory. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=see_link\">",
"     \"Clinical features and diagnosis of Takayasu arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXTRACRANIAL VERTEBRAL ARTERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of occlusive lesions of the proximal vertebral arteries are atherosclerotic. Among a series of 100 patients with angiographically documented vertebral artery lesions, 92 percent were atherosclerotic in origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the most common location of atherosclerotic occlusive disease within the posterior circulation is the proximal portion of the vertebral artery in the neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Atherosclerotic plaques may begin in the subclavian artery and extend into the ostia of the proximal extracranial vertebral arteries (ECVAs), or begin within the most proximal portion of the ECVAs. Occlusions most often occur within the first inch of the ECVAs. In contrast, atherosclerotic disease rarely involves the more distal ECVAs within the cervical spine or near the penetration of the arteries into the skull (",
"    <a class=\"graphic graphic_figure graphicRef59642 \" href=\"mobipreview.htm?10/27/10675\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Proximal vertebral artery disease can cause sudden-onset strokes or transient ischemic attacks (TIAs). The most frequently reported symptom during TIAs is dizziness. These vertebral artery TIAs are indistinguishable from those described by patients with subclavian steal, except that vertebral artery TIAs are not precipitated by effort or by arm exertion.",
"   </p>",
"   <p>",
"    Although dizziness is the most common symptom, it is seldom the only neurologic symptom. Usually, in at least some attacks, dizziness is accompanied by other signs of hindbrain ischemia. Diplopia, oscillopsia, weakness of both legs, hemiparesis, and numbness are often reported.",
"   </p>",
"   <p>",
"    In patients with proximal ECVA disease, a bruit can often be heard over the supraclavicular region when auscultation is performed by moving the stethoscope bell over the posterior cervical muscles and the mastoid. Sometimes a bruit may be heard over the vertebral artery contralateral to the side of the stenotic vertebral artery because of increased collateral blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Artery to artery embolism and low flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolization of white platelet-fibrin and red erythrocyte-fibrin thrombi from atherostenotic occlusive lesions is the most common presentation of extracranial vertebral artery (ECVA) origin disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1-5,8\">",
"     1-5,8",
"    </a>",
"    ]. The intraarterial emboli travel from the ECVA origin to reach the ipsilateral intracranial vertebral artery (ICVA), and sometimes travel on to block the rostral basilar artery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its branches. In support of this observation, patients presenting with ischemia in the distribution of the ICVA (the medulla and posterior inferior cerebellum) or the distal basilar artery (superior cerebellum, occipital and temporal lobes in the territory of the posterior cerebral arteries, or the thalamus or midbrain) show a high frequency of recent ECVA occlusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A situation analogous to that of ECVA origin disease is well known in the anterior circulation, where atherosclerotic disease of the internal carotid artery origin can cause distal ischemia by artery to artery embolization. As an example, it is not uncommon that a patient with a small, middle cerebral artery territory infarct is found to have an occlusion at the internal carotid artery origin by ultrasound or angiography. In most of these cases, it is likely that a recently formed occlusive thrombus in the internal carotid artery fragmented and embolized distally, causing the middle cerebral artery territory stroke.",
"   </p>",
"   <p>",
"    In patients with proximal ECVA stenosis, intraarterial (artery to artery) embolism is a much more frequent cause of ischemia to the intracranial posterior circulation arteries than hemodynamic insufficiency (ie, low flow). This point is illustrated by results from the New England Medical Center Posterior Circulation Registry, which evaluated a series of 407 patients who had posterior circulation TIAs or strokes within the prior six months and included 80 patients with severe stenosis or occlusion of the proximal ECVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1\">",
"     1",
"    </a>",
"    ]. In 45 (56 percent) of these 80 patients, embolization from the vertebral artery lesion was the most likely cause of brain ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1\">",
"     1",
"    </a>",
"    ]. Only 13 patients (16 percent) had hemodynamic-related TIAs, and 12 of these 13 had severe bilateral vertebral artery occlusive disease. The only patient with unilateral vertebral artery disease had bilateral internal carotid artery occlusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dissection and other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissection of the extracranial vertebral artery (ECVA) usually involves the distal portion of the ECVA as it winds around the upper cervical vertebrae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/9\">",
"     9",
"    </a>",
"    ]. Sometimes dissections involve the proximal ECVA between the origin of the artery and its entry into the vertebral column, usually at C5 or C6. Pain in the neck",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occiput and TIAs or strokes involving the lateral medulla and cerebellum are the most common findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10730?source=see_link&amp;anchor=H95541757#H95541757\">",
"     \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ischemic symptoms due to ECVA dissection are most often vestibulocerebellar and include dizziness, vertigo, veering to one side, and loss of balance. When infarcts develop, they usually involve the inferior portion of the cerebellum, causing gait ataxia. Less common, are emboli to the distal posterior circulation, especially the posterior cerebral artery territories, causing a hemianopia. Occasionally cervical root pain and signs, and spinal cord ischemia can develop.",
"   </p>",
"   <p>",
"    In older patients, giant cell arteritis is an occasional cause of occlusive disease involving the distal extracranial vertebral artery just before it penetrates the dura to become intracranial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INTRACRANIAL VERTEBRAL ARTERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherostenotic disease can involve any portion of the intracranial vertebral arteries (ICVA) (",
"    <a class=\"graphic graphic_figure graphicRef66585 \" href=\"mobipreview.htm?22/29/22999\">",
"     figure 2",
"    </a>",
"    ). The most common location of ICVA stenosis is the distal portion of the artery at or near the vertebral-basilar artery junction. Another common site of ICVA stenosis is the proximal portion of the vertebral artery just after dural penetration and before giving off the posterior inferior cerebellar artery (PICA) branch. Dissection of the ICVA also occurs, and ischemic symptoms are usually accompanied by prominent headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/10\">",
"     10",
"    </a>",
"    ]. ICVA dissections often extend into the basilar artery.",
"   </p>",
"   <p>",
"    Occlusive ICVA disease presents in a variety of different ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic occlusion",
"     </li>",
"     <li>",
"      TIAs, usually including vestibulocerebellar symptoms or elements of the lateral medullary syndrome",
"     </li>",
"     <li>",
"      Lateral medullary infarcts",
"     </li>",
"     <li>",
"      Medial medullary infarction",
"     </li>",
"     <li>",
"      Infarction of one-half of the medulla (hemimedullary infarction) including the lateral and medial medulla on one side",
"     </li>",
"     <li>",
"      Cerebellar infarction in PICA territory",
"     </li>",
"     <li>",
"      Embolization of the ICVA thrombus to the distal basilar artery and its branches causing TIAs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      strokes",
"     </li>",
"     <li>",
"      Propagation of the ICVA thrombus into the basilar artery causing a basilar artery syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lateral medullary infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral medullary infarction (Wallenberg syndrome) is the most common and important syndrome related to intracranial vertebral artery occlusion (",
"    <a class=\"graphic graphic_figure graphicRef62175 \" href=\"mobipreview.htm?15/6/15462\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. The diagnosis is often missed by non-neurologists, and so the features are very important to know and understand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Vestibulocerebellar symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibulocerebellar symptoms and signs are nearly always present in patients with lateral medullary infarcts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/11\">",
"     11",
"    </a>",
"    ]. These are related to involvement of the vestibular nuclei and their connections, and to involvement of the inferior cerebellar peduncle (restiform body). Common symptoms and signs are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Feeling dizzy or off-balance, which may take a number of forms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Turning, rotating, whirling or moving in relation to the environment",
"     </li>",
"     <li>",
"      Being pulled or falling towards one side, most often ipsilateral to the lesion",
"     </li>",
"     <li>",
"      Swaying or rolling as if moving from side to side",
"     </li>",
"     <li>",
"      Tilting or leaning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Difficulty sitting upright without support. Patients topple, lean, or veer to the ipsilateral side when they sit or stand. In many, standing or walking is impossible during the acute period without support. When they regain the ability to walk, patients often feel as if they are being pulled to the side of the lesion. They veer, list, or weave to the side, especially on turns.",
"     </li>",
"     <li>",
"      Hypotonia of the ipsilateral arm. This cerebellar sign can be demonstrated by having the patient quickly lower or raise the outstretched hands together, braking the ascent and descent suddenly. The symptomatic arm on the side ipsilateral to the infarct often overshoots and is not as quickly braked compared with the normal contralateral arm. In some patients, the ipsilateral arm also makes a slower ascent or descent.",
"     </li>",
"     <li>",
"      Blurred vision or diplopia. Some also describe oscillopsia, which is the appearance that objects in the visual field are in rhythmic motion or oscillation. Less common is tilting or inversion of the visual environment.",
"     </li>",
"     <li>",
"      Nystagmus. This is nearly always present, especially in patients who describe dizziness or vertigo. The nystagmus usually has both horizontal and rotational components. The rapid phase of the rotatory nystagmus usually moves the upper border of the iris towards the side of the lesion. Most often, larger amplitude, slower nystagmus is present on gaze to the side of the lesion, while smaller amplitude, quick nystagmus is found on gaze directed to the contralateral side.",
"     </li>",
"     <li>",
"      Ocular torsion. The eye and ear ipsilateral to the lateral medullary infarct may rest in a down position below the contralateral eye and ear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/13\">",
"       13",
"      </a>",
"      ]. At times, ocular torsion is accompanied by a head tilt and skew deviation with the ipsilateral eye positioned downward. This combination of findings is referred to as the ocular tilt reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/4,14,15\">",
"       4,14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limb ataxia ipsilateral to the lateral medullary infarct. Some patients cannot feed themselves using the ataxic arm. They overshoot targets and have difficulty pointing accurately to moving targets.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sensory symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory symptoms and signs are common in patients with lateral medullary infarcts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain or unpleasant feelings in the face are sometimes the earliest and most prominent feature of the lateral medullary syndrome and are diagnostic of a lateral tegmental brainstem localization. These are related to lesions of the spinal nucleus of V and the descending spinal tract of V. The facial pain is usually described as sharp jolts or stabs of pain most often in the ipsilateral eye or face. Sometimes pain persists and is limited to the forehead and frontal scalp region. At times, the abnormal sensation is described as hot, burning, or scalding.",
"     </li>",
"     <li>",
"      Loss of pain and temperature sensation in the contralateral trunk and limbs is related to lesions of the lateral medullary spinothalamic tract.",
"     </li>",
"     <li>",
"      The most common pattern of sensory abnormality with lateral medullary infarcts is loss of pain and temperature sensation in the ipsilateral face and the contralateral trunk and limbs. The next most frequent combination is hypalgesia in the ipsilateral face and contralateral face, trunk, and limbs. Less often, the hypalgesia can be solely contralateral, involving the face, arm, and leg, or sometimes only the face and arm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/4,16\">",
"       4,16",
"      </a>",
"      ]. The least common pattern of sensory loss is hypalgesia only involving the contralateral trunk, arm, and leg or parts thereof.",
"     </li>",
"     <li>",
"      Examination usually shows ipsilateral decreased pain and temperature sensation in the face. The corneal reflex is usually reduced in the ipsilateral eye. Although contralateral loss of pain and thermal sensation involving the body and limbs is usually found on examination, most patients with contralateral hypalgesia are unaware of their sensory loss until they are tested. However, some do notice loss of thermal sensation when they touch hot or cold objects with their contralateral upper",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lower limbs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bulbar muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness of bulbar muscles innervated by the lower cranial nerves is a very prominent feature when lateral medullary infarcts extend medially. Usually, the abnormality is unilateral.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involvement of the nucleus ambiguus causes paralysis of the ipsilateral palate, pharynx, and larynx, resulting in hoarseness and dysphagia. Oropharyngeal muscle paralysis results in food being trapped in the piriform recess of the pharynx. Food and secretions have relatively free access into the air passages. Patients try to extricate the food with a cough or throat-clearing maneuver, which makes a characteristic crowing-like sound.",
"     </li>",
"     <li>",
"      Examination shows paralysis of the ipsilateral vocal cord and a lack of elevation of the ipsilateral palate on phonation. The uvula often deviates to the side contralateral to the lateral medullary infarct. Dysarthria and dysphonia are common. In some patients, dysphagia and aspiration are prominent.",
"     </li>",
"     <li>",
"      Aspiration and pneumonia are very important complications of abnormal pharyngeal function. Hiccups are also a relatively common and annoying complaint.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Respiratory dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory dysfunction is an important feature of lateral medullary ischemia. Control of inspiration and expiration and their automaticity lies within the ventrolateral medullary tegmentum and the medullary reticular zone.",
"   </p>",
"   <p>",
"    The most common abnormality described in patients with lateral tegmental caudal brainstem lesions is failure of automatic respirations, a phenomenon especially apparent during sleep. This failure to initiate respiration has been referred to as Ondine's curse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22520?source=see_link&amp;anchor=H4#H4\">",
"     \"Disorders of ventilatory control\", section on 'Ondine's curse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic dysfunction may occur in lateral medullary infarction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ipsilateral eye often shows features of Horner's syndrome due to lesions of the descending sympathetic nervous system. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=see_link\">",
"       \"Horner's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiovascular abnormalities include tachycardia, orthostatic hypotension without cardiac rate acceleration, and intermittent bradycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/4\">",
"       4",
"      </a>",
"      ]. Some patients have labile blood pressures, tachycardia, unusual sweating, and arrhythmias. The anatomic basis is thought to be involvement of the dorsal motor nucleus of the vagus nerve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Medial medullary infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most consistent finding in patients with medial medullary ischemia is a contralateral hemiparesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. Usually the hemiparesis is complete and flaccid at onset. Later, increased tone and spasticity develop. In approximately one-half of patients, the face is also involved. Facial weakness, when it occurs, is usually slight and transient and rarely persists.",
"   </p>",
"   <p>",
"    Sensory symptoms are related to ischemia of the medial lemniscus. Some patients report paresthesias or, less commonly, dysesthesias in the contralateral lower limb and trunk. Less often, sensory symptoms occur in the arm and hand. In many patients with sensory symptoms there are no objective signs of touch, vibration, or position sense loss. Proprioceptive dysfunction, with slight loss of position and vibration sense in the contralateral foot, is found in some patients.",
"   </p>",
"   <p>",
"    Ipsilateral tongue paralysis is the least common but most topographically localizing sign of medial medullary infarction, and is due to involvement of the hypoglossal nucleus. Tongue paresis causes slurring of speech, especially of lingual consonants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hemimedullary infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients have infarction that involves both the lateral and medial medullary territories on one side (hemimedullary infarcts). Symptoms are identical to those found in patients with lateral medullary ischemia with the addition of a hemiparesis contralateral to the lesion. The hemiparesis may develop concurrently with lateral medullary symptoms and signs or can occur later. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Lateral medullary infarction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Medial medullary infarction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cerebellar infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebellar infarction in posterior inferior cerebellar artery (PICA) distribution can involve just the vermis, or the lateral surface, or the full PICA territory (",
"    <a class=\"graphic graphic_figure graphicRef73656 \" href=\"mobipreview.htm?7/16/7430\">",
"     figure 4",
"    </a>",
"    ). Full PICA territory infarcts are often accompanied by edema formation and mass effect (so-called pseudotumoral cerebellar infarcts). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Pseudotumoral cerebellar infarction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Approximately one-fifth of PICA territory cerebellar infarcts are accompanied by infarction in the dorsal or dorsolateral medulla [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The combination of lateral medullary and PICA cerebellar infarction occurs when the intracranial vertebral artery (ICVA) is occluded and blocks the orifice of both PICA and the lateral medullary penetrators. Sometimes medial PICA territory infarcts are accompanied by dorsal medullary infarcts since the medial PICA branch has some supply to the dorsal medulla [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/4,18,19\">",
"     4,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infarcts limited to the medial vermis in medial PICA territory usually cause a vertiginous labyrinthian syndrome that closely mimics a peripheral vestibulopathy. Severe vertigo and prominent nystagmus are the major findings. Some patients also have truncal lateropulsion characterized by feelings of magnetic pulling of the trunk to the ipsilateral side.",
"   </p>",
"   <p>",
"    Lateral cerebellar hemisphere PICA territory infarcts are usually characterized by minor degrees of dizziness and gait incoordination with veering to the side of the lesion. Minor limb hypotonia and incoordination are found. A common syndrome is acute unsteadiness with ataxia but without vertigo or dysarthria. Body sway towards the side of the lesion, ipsilateral limb ataxia, and abnormal rapid alternating movements are also common.",
"   </p>",
"   <p>",
"    When the full PICA cerebellar territory is involved, headache is usually present in the occiput or high neck on the ipsilateral side. The head may also be tilted with the occiput tending to tilt toward the ipsilateral side.",
"   </p>",
"   <p>",
"    Vomiting, gait ataxia, truncal lateropulsion, and limb incoordination are other common findings. The truncal dysfunction is similar to that found in the lateral medullary syndrome; the body is often tilted or pulled ipsilaterally upon sitting or standing. The limb incoordination consists mostly of hypotonia rather than a rhythmic intention tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pseudotumoral cerebellar infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of pseudotumoral cerebellar infarction, with edema formation and mass effect, is most often associated with large full posterior inferior cerebellar artery (PICA) territory infarcts. After the first day or so, patients with this form of cerebellar infarction typically develop increased headache, vomiting, and decreased consciousness, with drowsiness followed by stupor. Bilateral Babinski signs are an early sign of cerebellar mass effect.",
"   </p>",
"   <p>",
"    Characteristic oculomotor abnormalities of large cerebellar space-taking infarcts can develop and include the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most common are a conjugate gaze paresis to the side of the lesion or a paresis of abduction limited to the ipsilateral eye",
"     </li>",
"     <li>",
"      Bilateral sixth nerve paresis may occur",
"     </li>",
"     <li>",
"      Later bilateral horizontal gaze palsies may develop, often accompanied by ocular bobbing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These signs are due to compression of the pontine tegmentum by the swollen cerebellar infarct. Stupor is followed by deep coma when the oculomotor abnormalities become bilateral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dolichoectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dolichoectasia (dilatative arteriopathy) is a term that describes arterial elongation, widening, and tortuosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. The intracranial vertebral and basilar arteries are most often affected. Dolichoectatic arteries are characterized by an abnormally large external diameter and a thin arterial wall that shows degeneration of the internal elastic lamina, and multiple gaps in the internal elastica. The media of dilated arteries becomes thin because of reticular fiber deficiency and smooth muscle atrophy.",
"   </p>",
"   <p>",
"    The most important clinical presentations of dilatative arteriopathy are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute brain ischemia",
"     </li>",
"     <li>",
"      A progressive course related to compression of cranial nerves, the brainstem, or the third ventricle",
"     </li>",
"     <li>",
"      A catastrophic outcome caused by vascular rupture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flow in dilated arteries may become to-and-fro, causing reduced antegrade flow and thrombus formation. Elongation and angulation of arteries can stretch and distort the orifices of arterial branches leading to decreased blood flow, especially in penetrating branches. Dilated intracranial vertebral arteries can compress the medulla leading to the gradual onset of hemiparesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     BASILAR ARTERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basilar artery begins at the medullopontine junction and ends at the junction of the pons and midbrain. Occlusive lesions may occur anywhere along the basilar artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, thrombi engrafted upon occlusive lesions within the distal intracranial vertebral artery (ICVA), for example, near or at the ICVA-basilar artery junction, can extend into the proximal basilar artery.",
"   </p>",
"   <p>",
"    Basilar artery occlusive disease most often presents as ischemia in the pons. The major burden of ischemia is in the middle of the pons, mostly in the paramedian base, and often also in the paramedian tegmentum (",
"    <a class=\"graphic graphic_picture graphicRef81264 \" href=\"mobipreview.htm?0/55/885\">",
"     picture 1",
"    </a>",
"    ). The reasons for this localization are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest penetrating arteries supply the paramedian pons (",
"      <a class=\"graphic graphic_figure graphicRef69507 \" href=\"mobipreview.htm?23/62/24547\">",
"       figure 5",
"      </a>",
"      ) and arise directly from the basilar artery.",
"     </li>",
"     <li>",
"      The pontine tegmentum is supplied mostly by arteries that arise from the distal basilar artery. When the distal basilar artery remains patent, the tegmentum is relatively spared.",
"     </li>",
"     <li>",
"      Collateral circulation comes mainly from the ICVAs through their posterior inferior cerebellar artery (PICA) branches that anastomose with anterior inferior cerebellar artery (AICA) and superior cerebellar artery (SCA) branches; these course around the lateral aspect of the pons, supplying the lateral tegmental and basal structures in the pons (",
"      <a class=\"graphic graphic_figure graphicRef73656 \" href=\"mobipreview.htm?7/16/7430\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61444 \" href=\"mobipreview.htm?20/57/21397\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The paramedian pontine base contains descending long motor tract and crossing cerebellar fibers. The paramedian tegmentum contains mostly oculomotor fibers. As a result, the predominant symptoms and signs in patients with basilar artery occlusive disease are motor and oculomotor. Sensory and vestibular nuclei and tracts located in the lateral tegmentum are relatively spared.",
"   </p>",
"   <p>",
"    Alteration in the level of consciousness is an important sign in patients with basilar artery occlusion. They may present with coma when the bilateral medial pontine tegmentum is ischemic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Motor symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with symptomatic basilar artery occlusive disease and pontine ischemia have some transient or persistent degree of paresis and corticospinal tract abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/3,4,11,26-29\">",
"     3,4,11,26-29",
"    </a>",
"    ]. The initial motor weakness is often lateralized and has been referred to as the \"herald hemiparesis\" of basilar artery occlusion.",
"   </p>",
"   <p>",
"    Hemiparetic patients with basilar artery occlusion almost always show some motor or reflex abnormalities on the nonhemiparetic side. As examples, slight weakness, hyperreflexia, an extensor plantar reflex, or abnormal spontaneous movements such as shivering, twitching, shaking, or jerking may be present on the relatively spared side. Asymmetry but bilaterality is the rule.",
"   </p>",
"   <p>",
"    Adventitious movements of the arms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    legs are occasionally seen and can be prominent. These movements are variable and sometimes intermittent. Small movements may resemble fasciculations. Larger movements may resemble shivering, shuddering, or jerking; another variant is that of tremulous shaking. Voluntary or passive limb movements or painful stimuli may precipitate a flurry of abnormal movements. At times there are large repetitive jerking and twitching movements, especially in limbs contralateral to a hemiparesis. These movements are often misdiagnosed as seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incoordination of limb movements is another common motor finding. Ataxia is invariably combined with some degree of weakness. Incoordination is usually more severe in the legs. Toe-to-object and heel-to-shin testing usually shows clumsiness and diminished coordination due to cerebellar dysfunction. The ataxia is invariably bilateral but may be asymmetric and more severe on the weaker side. Intention tremor is not common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Bulbar involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness of bulbar muscles is very common and is an important cause of morbidity with pontine infarction due to basilar occlusive disease. Bulbar symptoms include facial weakness, dysphonia, dysarthria, dysphagia, and limited jaw movements. The face, pharynx, larynx, and tongue are most often involved. The pattern may be that of crossed motor loss, such as weakness involving one side of the face and the contralateral body, but more often the bulbar muscle weakness is bilateral.",
"   </p>",
"   <p>",
"    Some patients totally lose the ability to speak, open their mouth, protrude their tongue, swallow, or move their face at will or on command. Secretions pool in the pharynx; and aspiration is an important and serious complication. When all voluntary movements other than the eyes are lost but consciousness is retained, the deficit is referred to as the \"locked-in syndrome.\" (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/63/34807?source=see_link\">",
"     \"Locked-in syndrome\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Patients with infarction of the pontine base frequently have exaggerated crying and laughing spells and are hypersensitive to emotional stimulus, a condition known as pseudobulbar affect or emotional lability.",
"   </p>",
"   <p>",
"    Despite the loss of volitional muscle movement, reflexes of the jaw, face, and pharynx may be exaggerated. In addition, clonic jaw movements or clamping down on a tongue blade may occur as a response to attempts to pry the mouth open and to insert a tongue blade.",
"   </p>",
"   <p>",
"    Some patients with pontine ischemia develop palatal myoclonus (a rhythmic involuntary jerking movement of the soft palate and pharyngopalatine arch) that can involve the diaphragm and larynx. This movement disorder usually begins sometime after the brainstem infarct. The movements of the palate vary in rate between 40 and 200 beats per minute. The movements are readily seen by watching the palate and pharynx when the mouth is open. The movements involve the eustachian tube and make a click that the patient and clinician can hear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Oculomotor symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oculomotor symptoms and signs are common with symptomatic basilar artery occlusive disease and pontine ischemia, and few patients with this condition have normal eye movements. Abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete bilateral horizontal gaze palsy",
"     </li>",
"     <li>",
"      Unilateral horizontal conjugate gaze palsy",
"     </li>",
"     <li>",
"      Unilateral or bilateral internuclear ophthalmoplegia (INO)",
"     </li>",
"     <li>",
"      One-and-a-half syndrome (a conjugate gaze palsy combined with an INO).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skew deviation of the eyes and ocular bobbing may also be present. Horizontal, gaze-paretic nystagmus is common and, when asymmetric, usually is more prominent when gaze is directed to the side of a unilateral pontine tegmental lesion. Dissociated nystagmus, that is nystagmus that is more severe in one eye and not rhythmically concordant in the two eyes, and vertical nystagmus are found in patients with an INO. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=see_link\">",
"     \"Internuclear ophthalmoplegia\"",
"    </a>",
"    .) Ptosis of the upper eyelids is also very frequent.",
"   </p>",
"   <p>",
"    The pupils may remain normal or become small. In some patients, the pupils are bilaterally very small (\"pinpoint\"). Use of a magnifying glass can show that, despite their very small size, the pupillary response to light is preserved, although the amplitude of the response is slight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sensory symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatosensory abnormalities are generally not prominent in patients with basilar artery occlusions. Paresthesias on one side of the body and limbs reflect involvement of the contralateral medial lemniscus in the paramedian dorsal portion of the basis pontis. Bilateral paramedian lesions that include the medial lemnisci on both sides can cause bilateral paresthesias. Proprioceptive loss is usually minimal or absent despite the paresthesias.",
"   </p>",
"   <p>",
"    Some patients with basilar artery occlusive disease have unusual burning pain in the face usually located in the center of the face near the midline. Tinnitus and hearing loss relate to involvement of the central auditory tracts and nuclei (auditory nuclei, lateral lemnisci, trapezoid bodies, inferior colliculi) or to ischemia of the eighth nerves or the cochlea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ROSTRAL BRAINSTEM ISCHEMIA AND \"TOP OF THE BASILAR\" SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occlusion of the rostral portion of the basilar artery (the \"top of the basilar\") can cause ischemia of the midbrain, thalami, and temporal and occipital lobe hemispheral territories supplied by the posterior cerebral artery branches of the basilar artery.",
"   </p>",
"   <p>",
"    In most patients, infarction in this region &ndash; the top of the basilar &ndash; is caused by embolism from a more proximal source such as the heart, the aorta, the vertebral arteries in the neck, or the intracranial vertebral arteries. Less commonly, the syndrome is caused by intrinsic occlusive disease of the rostral portion of the basilar artery. In many patients infarction is limited to the rostral brainstem.",
"   </p>",
"   <p>",
"    The major abnormalities associated with rostral brainstem infarction involve alertness, behavior, memory, and oculomotor and pupillary functions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Oculomotor and pupillary abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common abnormalities of eye position and movement involve vertical gaze and convergence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/3,31,32\">",
"     3,31,32",
"    </a>",
"    ]. Some patients lose all voluntary and reflex vertical eye movements. Reflex movements are sometimes preserved despite loss of voluntary vertical eye movements. Either upgaze or downgaze can be selectively involved, but in most patients both directions of vertical gaze are involved. Upgaze and vertical gaze palsies are more common than downgaze palsies.",
"   </p>",
"   <p>",
"    Asymmetric or unilateral lesions in the midbrain tegmentum and posterior thalami can cause ocular tilt reactions in which the contralateral eye and ear are down. Other abnormalities include skew deviation, ocular torsion, and abnormal estimation of the visual vertical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Convergence abnormalities are also very common. Usually one or both eyes are hyperconverged. One or both eyes may rest inward or down and in at rest. On attempted upgaze, the eyes may show adductor contractions, causing convergence movements.",
"   </p>",
"   <p>",
"    A rostral mesencephalic lesion near the level of the posterior commissure can cause pathologic retraction of the upper eyelid with widening of the palpebral fissure (Collier sign). In some patients, both lids are retracted but one eye may have a normal lid position or ptosis.",
"   </p>",
"   <p>",
"    Lesions in the rostral brainstem also often affect the pupillary light reflex so that the pupils react slowly and incompletely, or not at all, to light. In patients with diencephalic lesions, the pupils are often small at rest, and may be fixed and dilated if the lesions involve the third nerve Edinger-Westphal nuclei. A combination of diencephalic and midbrain lesions may cause mid-position fixed pupils.",
"   </p>",
"   <p>",
"    The constellation of neuroophthalmologic findings seen with midbrain (pretectal) lesions has been called Parinaud syndrome (",
"    <a class=\"graphic graphic_table graphicRef81227 \" href=\"mobipreview.htm?11/52/12107\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Altered alertness, behavior, and memory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of alertness and behavior are common in patients with rostral brainstem infarcts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/11\">",
"     11",
"    </a>",
"    ]. Hypersomnolence and abulia are common. Patients may answer queries with replies that have no relation to reality. The patient may mislocate themselves in place, reporting that they are in a distant geographical location, and in the personal time dimension, saying that they are presently performing activities that they had actually done in childhood, adolescence, or much earlier in adult life.",
"   </p>",
"   <p>",
"    Thalamic or midbrain injury that \"straddles the peduncles\" can lead to peduncular hallucinations. These are predominantly visual, but there may be some minor tactile and auditory components. Visual hallucinations are often quite vivid and contain colors, objects, and scenes. The hallucinations occur predominantly after sundown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/3,31\">",
"     3,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/36/42569?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the patient with visual hallucinations\", section on 'Peduncular hallucinosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prominent and sometimes persistent memory deficits may develop with rostral brainstem infarcts that include the thalamus. The amnesia involves both anterograde and retrograde memory and usually includes both verbal and nonverbal memory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory and motor abnormalities are usually absent in patients with top of the basilar infarction. Movement disorders, especially hemiballism, have been described in some patients with small infarcts and hemorrhages involving the subthalamic nuclei, but hemiballism is rare in patients with well-documented \"top of the basilar\" infarcts.",
"   </p>",
"   <p>",
"    The superior portion of the cerebellum may also be infarcted, since the superior cerebellar arteries branch from the distal end of the basilar artery. Common symptoms are slight dizziness, vomiting, ipsilateral limb dysmetria, gait ataxia, and dysarthria. Vertigo is usually not prominent. Limb incoordination, intention tremor, and dysarthria are more common with superior cerebellar artery territory infarcts than with infarcts involving the territory of other cerebellar arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     POSTERIOR CEREBRAL ARTERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most posterior cerebral artery (PCA) territory infarcts are due to embolism from the heart, aorta, or vertebral arteries. Atherosclerosis and dissection of the PCAs is not common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Visual loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent finding in patients with PCA territory infarction is a hemianopia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1-4,33-35\">",
"     1-4,33-35",
"    </a>",
"    ]. At times, the central or medial part of the field is spared, so-called macular sparing. A superior quadrant field defect results if the infarct involves just the lower bank of the calcarine fissure (the lingual gyrus). An inferior quadrantanopia results if the lesion affects the cuneus on the upper bank of the calcarine fissure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37848?source=see_link\">",
"     \"Homonymous hemianopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the full PCA territory is involved, visual neglect can accompany the hemianopia. However, patients are aware of the visual defect when infarcts are restricted to the striate cortex and do not extend into the adjacent parietal cortex. The visual defect is often described as a void, blackness, or a limitation of vision to one side, and patients usually recognize that they must focus extra attention to the hemianopic field. When given written material or pictures, patients with hemianopia due to occipital lobe infarction are able to see and interpret stimuli normally, although it may take somewhat longer to explore the hemianopic visual field.",
"   </p>",
"   <p>",
"    Clinicians can reliably map out the visual fields by confrontation in patients with occipital lobe infarcts. Optokinetic nystagmus is preserved. Some patients, although they accurately report motion or the presence of objects in their hemianopic field, cannot identify the nature, location, or color of those objects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Sensory and motor abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with PCA territory ischemia, lateral thalamic infarction is the major reason for somatosensory symptoms and signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients describe paresthesias or numbness in the face, limbs, and trunk. On examination, touch, pinprick, and position sense are reduced.",
"   </p>",
"   <p>",
"    The combination of hemisensory loss and hemianopia without paralysis is virtually diagnostic of infarction in the PCA territory. The occlusive lesion is within the PCA before the thalamogeniculate branches to the lateral thalamus. Rarely, occlusion of the proximal portion of the PCA causes a hemiplegia, which is probably due to infarction in the lateral midbrain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/3,37-39\">",
"     3,37-39",
"    </a>",
"    ]. Involvement of the corticospinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corticobulbar tracts in the cerebral peduncles is thought to cause hemiplegia in these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Left PCA territory symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the left PCA territory is infarcted, alexia without agraphia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/40-43\">",
"     40-43",
"    </a>",
"    ], anomic aphasia or transcortical sensory aphasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/44\">",
"     44",
"    </a>",
"    ], and Gerstmann syndrome (acalculia, agraphia, finger agnosia, and right-left disorientation) may be found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/3,40\">",
"     3,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Defective acquisition of new memories is common when both medial temporal lobes are damaged but also occurs in lesions limited to the left temporal lobe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/3,40,45,46\">",
"     3,40,45,46",
"    </a>",
"    ]. The memory deficit in patients with unilateral lesions is usually not permanent but may last up to six months. Patients cannot recall what has happened recently and, when given new information, they do not recall it moments later. They often repeat statements and questions spoken only minutes before.",
"   </p>",
"   <p>",
"    Some patients with left PCA territory infarction have difficulty in understanding the nature and use of objects presented visually (associative visual agnosia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/40,43\">",
"     40,43",
"    </a>",
"    ]. They can trace with their fingers and copy objects, demonstrating that visual perception is preserved; they can name objects presented in their hand and explored by touch or when verbally described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Right PCA territory symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infarcts of the right PCA territory are often accompanied by prosopagnosia, which is difficulty in recognizing familiar faces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/43,47\">",
"     43,47",
"    </a>",
"    ]. Disorientation to place and an inability to recall routes or to read or visualize the location of places on maps are also common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39273/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with right occipitotemporal infarcts also may have difficulty visualizing what a given object or person look like. Dreams may be devoid of visual imagery.",
"   </p>",
"   <p>",
"    Visual neglect is much more common after lesions of the right than of the left PCA territory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149298737\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of posterior circulation large artery ischemia are atherosclerosis, embolism, and dissection. Dolichoectasia (elongation and tortuosity) of the vertebral and basilar arteries is another occasional cause. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Source of ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atherostenotic lesions of the innominate and subclavian arteries cause arm ischemia and transient ischemic attacks but seldom cause strokes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Subclavian and innominate arteries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of occlusive lesions of the proximal vertebral arteries are atherosclerotic. The most common location of atherosclerotic occlusive disease within the posterior circulation is the proximal portion of the vertebral artery in the neck (",
"      <a class=\"graphic graphic_figure graphicRef59642 \" href=\"mobipreview.htm?10/27/10675\">",
"       figure 1",
"      </a>",
"      ). In patients with proximal extracranial vertebral artery (ECVA) stenosis, intraarterial (artery-to-artery) embolism to the intracranial posterior circulation is a much more frequent cause of ischemia arteries than hemodynamic insufficiency (ie, low flow). The most frequently reported symptom during TIAs is dizziness. Diplopia, oscillopsia, bilateral leg weakness, hemiparesis, and numbness are often reported. Patients presenting with ischemia in the distribution of the intracranial vertebral arteries (the medulla and posterior inferior cerebellum) or the distal basilar artery (superior cerebellum, occipital and temporal lobes in the territory of the posterior cerebral arteries, or the thalamus or midbrain) show a high frequency of recent ECVA occlusions. Dissection of the ECVA usually involves the distal portion of the ECVA as it winds around the upper cervical vertebrae. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Extracranial vertebral arteries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atherostenotic disease can involve any portion of the intracranial vertebral arteries (ICVA) (",
"      <a class=\"graphic graphic_figure graphicRef66585 \" href=\"mobipreview.htm?22/29/22999\">",
"       figure 2",
"      </a>",
"      ). Occlusive ICVA disease presents in a variety of different ways (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Intracranial vertebral arteries'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asymptomatic occlusion",
"     </li>",
"     <li>",
"      TIAs, usually including vestibulocerebellar symptoms or elements of the lateral medullary syndrome",
"     </li>",
"     <li>",
"      Lateral medullary infarcts (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Lateral medullary infarction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Medial medullary infarction (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Medial medullary infarction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Infarction of one-half of the medulla including the lateral and medial medulla on one side (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Hemimedullary infarction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cerebellar infarction in posterior inferior cerebellar artery territory (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Cerebellar infarction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Embolization of the ICVA thrombus to the distal basilar artery and its branches causing TIAs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      strokes",
"     </li>",
"     <li>",
"      Propagation of the ICVA thrombus into the basilar artery causing a basilar artery syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basilar artery occlusive disease most often presents as ischemia in the pons. The major burden of ischemia is in the middle of the pons, mostly in the paramedian base, and often also in the paramedian tegmentum (",
"      <a class=\"graphic graphic_picture graphicRef81264 \" href=\"mobipreview.htm?0/55/885\">",
"       picture 1",
"      </a>",
"      ). Most patients with symptomatic basilar artery occlusive disease and pontine ischemia have some transient or persistent degree of paresis and corticospinal tract abnormalities. Bulbar symptoms include facial weakness, dysphonia, dysarthria, dysphagia, and limited jaw movements. Oculomotor symptoms and signs are common. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Basilar artery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occlusion of the rostral portion of the basilar artery (the \"top of the basilar\") can cause ischemia of the midbrain, thalami, and temporal and occipital lobe hemispheral territories supplied by the posterior cerebral artery branches of the basilar artery. Infarction in this region is typically caused by embolism from a more proximal source such as the heart, the aorta, the vertebral arteries in the neck, or the intracranial vertebral arteries. Less commonly, the syndrome is caused by intrinsic occlusive disease of the rostral portion of the basilar artery. The major abnormalities associated with rostral brainstem infarction involve alertness, behavior, memory, and oculomotor and pupillary functions. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Rostral brainstem ischemia and \"top of the basilar\" syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most posterior cerebral artery (PCA) territory infarcts are due to embolism from the heart, aorta, or vertebral arteries. Atherosclerosis and dissection of the PCAs is not common. The most frequent finding in patients with PCA territory infarction is a hemianopia. Lateral thalamic infarction is the major reason for somatosensory symptoms and signs. Additional neurologic syndromes found with infarction of the left PCA territory include alexia without agraphia, anomic aphasia or transcortical sensory aphasia, and Gerstmann syndrome (acalculia, agraphia, finger agnosia, and right-left disorientation). Syndromes observed with right PCA territory infarction include prosopagnosia, which is difficulty in recognizing familiar faces, spatial disorientation, and visual neglect. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Posterior cerebral arteries'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/1\">",
"      Caplan LR, Wityk RJ, Glass TA, et al. New England Medical Center Posterior Circulation registry. Ann Neurol 2004; 56:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/2\">",
"      Savitz SI, Caplan LR. Vertebrobasilar disease. N Engl J Med 2005; 352:2618.",
"     </a>",
"    </li>",
"    <li>",
"     Caplan LR. Posterior Circulation Disease: clinical findings, diagnosis, and management, Blackwell Science, Boston 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/4\">",
"      Caplan L. Posterior circulation ischemia: then, now, and tomorrow. The Thomas Willis Lecture-2000. Stroke 2000; 31:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/5\">",
"      Wityk RJ, Chang HM, Rosengart A, et al. Proximal extracranial vertebral artery disease in the New England Medical Center Posterior Circulation Registry. Arch Neurol 1998; 55:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/6\">",
"      Brewster DC, Moncure AC, Darling RC, et al. Innominate artery lesions: problems encountered and lessons learned. J Vasc Surg 1985; 2:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/7\">",
"      Labauge R, Boukobza M, Pag&egrave;s M, et al. [Occlusion of the vertebral artery (100 personal cases)]. Rev Neurol (Paris) 1987; 143:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/8\">",
"      Caplan LR, Amarenco P, Rosengart A, et al. Embolism from vertebral artery origin occlusive disease. Neurology 1992; 42:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/9\">",
"      Caplan LR. Dissections of brain-supplying arteries. Nat Clin Pract Neurol 2008; 4:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/10\">",
"      Caplan LR, Baquis GD, Pessin MS, et al. Dissection of the intracranial vertebral artery. Neurology 1988; 38:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/11\">",
"      Searls DE, Pazdera L, Korbel E, et al. Symptoms and signs of posterior circulation ischemia in the new England medical center posterior circulation registry. Arch Neurol 2012; 69:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/12\">",
"      Kim JS. Pure lateral medullary infarction: clinical-radiological correlation of 130 acute, consecutive patients. Brain 2003; 126:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/13\">",
"      Morrow MJ, Sharpe JA. Torsional nystagmus in the lateral medullary syndrome. Ann Neurol 1988; 24:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/14\">",
"      Brandt T, Dieterich M. Vestibular syndromes in the roll plane: topographic diagnosis from brainstem to cortex. Ann Neurol 1994; 36:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/15\">",
"      Keane JR. Ocular tilt reaction following lateral pontomedullary infarction. Neurology 1992; 42:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/16\">",
"      Matsumoto S, Okuda B, Imai T, Kameyama M. A sensory level on the trunk in lower lateral brainstem lesions. Neurology 1988; 38:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/17\">",
"      Tyler KL, Sandberg E, Baum KF. Medical medullary syndrome and meningovascular syphilis: a case report in an HIV-infected man and a review of the literature. Neurology 1994; 44:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/18\">",
"      Amarenco P, Hauw JJ. [Anatomy of the cerebellar arteries]. Rev Neurol (Paris) 1989; 145:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/19\">",
"      Amarenco P, Hauw JJ, H&eacute;nin D, et al. [Cerebellar infarction in the area of the posterior cerebellar artery. Clinicopathology of 28 cases]. Rev Neurol (Paris) 1989; 145:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/20\">",
"      Passero S, Filosomi G. Posterior circulation infarcts in patients with vertebrobasilar dolichoectasia. Stroke 1998; 29:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/21\">",
"      Pico F, Labreuche J, Seilhean D, et al. Association of small-vessel disease with dilatative arteriopathy of the brain: neuropathologic evidence. Stroke 2007; 38:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/22\">",
"      Passero SG, Rossi S. Natural history of vertebrobasilar dolichoectasia. Neurology 2008; 70:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/23\">",
"      Savitz SI, Ronthal M, Caplan LR. Vertebral artery compression of the medulla. Arch Neurol 2006; 63:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/24\">",
"      Lou M, Caplan LR. Vertebrobasilar dilatative arteriopathy (dolichoectasia). Ann N Y Acad Sci 2010; 1184:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/25\">",
"      Pessin MS, Gorelick PB, Kwan ES, Caplan LR. Basilar artery stenosis: middle and distal segments. Neurology 1987; 37:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/26\">",
"      KUBIK CS, ADAMS RD. Occlusion of the basilar artery; a clinical and pathological study. Brain 1946; 69:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/27\">",
"      Labauge R, Pages M, Marty-Double C, et al. [Occlusion of the basilar artery. A review with 17 personal cases (author's transl)]. Rev Neurol (Paris) 1981; 137:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/28\">",
"      Ferbert A, Br&uuml;ckmann H, Drummen R. Clinical features of proven basilar artery occlusion. Stroke 1990; 21:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/29\">",
"      Voetsch B, DeWitt LD, Pessin MS, Caplan LR. Basilar artery occlusive disease in the New England Medical Center Posterior Circulation Registry. Arch Neurol 2004; 61:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/30\">",
"      Ropper AH. 'Convulsions' in basilar artery occlusion. Neurology 1988; 38:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/31\">",
"      Caplan LR. \"Top of the basilar\" syndrome. Neurology 1980; 30:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/32\">",
"      Mehler MF. The neuro-ophthalmologic spectrum of the rostral basilar artery syndrome. Arch Neurol 1988; 45:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/33\">",
"      Pessin MS, Lathi ES, Cohen MB, et al. Clinical features and mechanism of occipital infarction. Ann Neurol 1987; 21:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/34\">",
"      Fisher CM. The posterior cerebral artery syndrome. Can J Neurol Sci 1986; 13:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/35\">",
"      Yamamoto Y, Georgiadis AL, Chang HM, Caplan LR. Posterior cerebral artery territory infarcts in the New England Medical Center Posterior Circulation Registry. Arch Neurol 1999; 56:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/36\">",
"      Georgiadis AL, Yamamoto Y, Kwan ES, et al. Anatomy of sensory findings in patients with posterior cerebral artery territory infarction. Arch Neurol 1999; 56:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/37\">",
"      Hommel M, Besson G, Pollak P, et al. Hemiplegia in posterior cerebral artery occlusion. Neurology 1990; 40:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/38\">",
"      Benson DF, Tomlinson EB. Hemiplegic syndrome of the posterior cerebral artery. Stroke 1971; 2:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/39\">",
"      North K, Kan A, de Silva M, Ouvrier R. Hemiplegia due to posterior cerebral artery occlusion. Stroke 1993; 24:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/40\">",
"      Caplan LR, Hedley-Whyte T. Cuing and memory dysfunction in alexia without agraphia. A case report. Brain 1974; 97:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/41\">",
"      Geschwind N. Disconnexion syndromes in animals and man. I. Brain 1965; 88:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/42\">",
"      Geschwind N, Fusillo M. Color-naming defects in association with alexia. Arch Neurol 1966; 15:137.",
"     </a>",
"    </li>",
"    <li>",
"     Barton JS, Caplan LR. Cerebral visual dysfunction. In: Stroke Syndromes, 2nd edition, Bogousslavsky J, Caplan LR (Eds), Cambridge University Press, Cambridge 2001. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/44\">",
"      Kertesz A, Sheppard A, MacKenzie R. Localization in transcortical sensory aphasia. Arch Neurol 1982; 39:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/45\">",
"      Benson DF, Marsden CD, Meadows JC. The amnesic syndrome of posterior cerebral artery occlusion. Acta Neurol Scand 1974; 50:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/46\">",
"      Ott BR, Saver JL. Unilateral amnesic stroke. Six new cases and a review of the literature. Stroke 1993; 24:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/47\">",
"      Damasio AR, Damasio H, Van Hoesen GW. Prosopagnosia: anatomic basis and behavioral mechanisms. Neurology 1982; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39273/abstract/48\">",
"      Fisher CM. Disorientation for place. Arch Neurol 1982; 39:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1102 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39273=[""].join("\n");
var outline_f38_22_39273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H149298737\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCE OF ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SUBCLAVIAN AND INNOMINATE ARTERIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXTRACRANIAL VERTEBRAL ARTERIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Artery to artery embolism and low flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dissection and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INTRACRANIAL VERTEBRAL ARTERIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lateral medullary infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Vestibulocerebellar symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sensory symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bulbar muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Respiratory dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Medial medullary infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hemimedullary infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cerebellar infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pseudotumoral cerebellar infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dolichoectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      BASILAR ARTERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Motor symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Bulbar involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Oculomotor symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sensory symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ROSTRAL BRAINSTEM ISCHEMIA AND \"TOP OF THE BASILAR\" SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Oculomotor and pupillary abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Altered alertness, behavior, and memory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      POSTERIOR CEREBRAL ARTERIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Visual loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Sensory and motor abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Left PCA territory symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Right PCA territory symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H149298737\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1102|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/57/21397\" title=\"diagnostic image 1\">",
"      Collateral flow in basilar artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1102|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/27/10675\" title=\"figure 1\">",
"      Extracranial vertebral arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/29/22999\" title=\"figure 2\">",
"      Posterior circulation to the brain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/6/15462\" title=\"figure 3\">",
"      Lateral medullary infarct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/16/7430\" title=\"figure 4\">",
"      Cerebellar arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/62/24547\" title=\"figure 5\">",
"      Vascular supply of the pons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1102|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/55/885\" title=\"picture 1\">",
"      Pontine infarct from basilar artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/52/12107\" title=\"table 1\">",
"      Parinaud syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/36/42569?source=related_link\">",
"      Approach to the patient with visual hallucinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/19/13624?source=related_link\">",
"      Clinical features and diagnosis of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37848?source=related_link\">",
"      Homonymous hemianopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=related_link\">",
"      Internuclear ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/61/2010?source=related_link\">",
"      Intracranial large artery atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/63/34807?source=related_link\">",
"      Locked-in syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10730?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/39/36471?source=related_link\">",
"      Subclavian steal syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_22_39274="Cystic fibrosis: Overview of the treatment of lung disease";
var content_f38_22_39274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystic fibrosis: Overview of the treatment of lung disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39274/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39274/contributors\">",
"     Richard H Simon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39274/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/22/39274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/22/39274/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/22/39274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) is a multisystem disorder caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, located on chromosome 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/1\">",
"     1",
"    </a>",
"    ]. Pulmonary disease remains the leading cause of morbidity and mortality in patients with CF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of CF lung disease is experiencing a period of rapid evolution, supported by well-designed clinical trials and improved understanding of the genetics and pathophysiology of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Undoubtedly, these advancements are responsible for a substantial portion of the improvement that has occurred in patient survival (",
"    <a class=\"graphic graphic_figure graphicRef61930 \" href=\"mobipreview.htm?25/23/25981\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    While the focus of this discussion is on pulmonary therapies, it must be kept in mind that management is often suboptimal unless the multisystem nature of the disease is considered. Sinus infection, nutritional status, glucose control, and psychosocial issues must all be assessed at regular intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/6\">",
"     6",
"    </a>",
"    ]. This requires a multidisciplinary approach to care that, in the United States, is best provided at one of the approximately 115 CF Care Centers (most with dedicated adult care programs) that are supported and accredited by the Cystic Fibrosis Foundation. Patients treated at these centers are seen on a regular basis by physicians, nurses, dietitians, respiratory therapists, physical therapists, and social workers with special competence in CF care. A listing of these centers can be obtained at the Cystic Fibrosis Foundation Web site (",
"    <a class=\"external\" href=\"file://www.cff.org/\">",
"     www.cff.org",
"    </a>",
"    ). In the United Kingdom, CF patients receiving their medical care at specialized CF centers have better clinical outcomes compared to patients followed in the general community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/7\">",
"     7",
"    </a>",
"    ]. In the United States, more frequent caregiver-patient interaction (visit frequency, monitoring, and interventions for pulmonary exacerbations) is associated with improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the treatment of CF lung disease will be reviewed here. Details of treatment with antibiotics are discussed separately. The diagnosis, clinical manifestations, and investigational treatments for CF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=see_link\">",
"     \"Cystic fibrosis: Investigational therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20592751\">",
"    <span class=\"h1\">",
"     CFTR MODULATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/58/22437?source=see_link\">",
"     Ivacaftor",
"    </a>",
"    (VX-770) is a small molecular weight oral drug that is specifically designed to treat patients who have a G551D mutation in at least one of their CFTR genes. As of January, 2012, ivacaftor is available and approved in the United States for patients with this mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/9\">",
"     9",
"    </a>",
"    ]. Of considerable importance, ivacaftor is the first approved CF therapy that restores the functioning of a mutant CF protein rather than trying to target one or more of its downstream consequences. The magnitude and breadth of its beneficial effects significantly exceed any other treatment currently available for cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The G551D mutation, which occurs in approximately 5 percent of CF patients, impairs the regulated activation of the ion channel that is formed by the CFTR protein. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=see_link&amp;anchor=H7#H7\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\", section on 'Class III mutations: Defective regulation'",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/58/22437?source=see_link\">",
"     Ivacaftor",
"    </a>",
"    was developed using high-throughput screening of large chemical libraries, by which candidate molecules (called &ldquo;potentiators&rdquo;) were identified that increased chloride ion flux in cultured cells expressing G551D CFTR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/11\">",
"     11",
"    </a>",
"    ]. From these candidate molecules, ivacaftor was developed.",
"   </p>",
"   <p>",
"    Clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/58/22437?source=see_link\">",
"     ivacaftor",
"    </a>",
"    have demonstrated important benefits. In a phase 3 multicenter randomized trial of 161 subjects 12 years of age or older with a G551D mutation, ivacaftor for 24 weeks improved mean FEV1 percent predicted by 10.4 percent compared to a decline by 0.2 percent in subjects receiving a placebo (primary endpoint, p &lt;0.001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/12\">",
"     12",
"    </a>",
"    ]. The beneficial effect was maintained through 48 weeks of ivacaftor treatment. Ivacaftor also decreased sweat chloride values by 48.1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    compared with that in the placebo group (p &lt;0.001), bringing the mean value in the ivacaftor group to 51.7",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    which is below the cutoff point of 60",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    that is used for diagnosing cystic fibrosis. Finally, treatment with ivacaftor reduced the frequency of pulmonary exacerbations (55 percent reduction in risk), improved pulmonary symptoms, and resulted in a significant weight gain of 2.7 kg after 48 weeks of treatment. The frequency of serious adverse events was lower in the ivacaftor group than in the placebo-treated patients. Another randomized, blinded, placebo controlled trial of 52 subjects age 6 to 11 years and at least one G551D CFTR mutation found similar improvements in lung function (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00909727?term=NCT00909727&amp;rank=1\">",
"     NCT00909727",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All CF patients should undergo CFTR genotyping to determine if they carry a G551D mutation in their CFTR genes. Because this mutation was identified in 1990, it is highly likely that most CF patients who were genotyped after the early 1990s would have G551D identified if it was present.",
"   </p>",
"   <p>",
"    We recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/58/22437?source=see_link\">",
"     ivacaftor",
"    </a>",
"    for all CF patients 6 years of age and older who carry at least one copy of the G551D CFTR mutation. Ivacaftor, 150 mg PO every 12 hours, should be taken with fat-containing foods. Dose reductions are needed for patients with hepatic impairment or who are taking drugs that are inhibitors of cytochrome P4503A such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (see",
"    <a class=\"external\" href=\"file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203188lbl.pdf\">",
"     manufacturer&rsquo;s prescribing information",
"    </a>",
"    ). Because elevations in serum hepatic enzyme levels were noted in a small number of subjects during clinical trials, liver function tests are recommended prior to ivacaftor treatment, every three months for the first year, and then annually thereafter. &nbsp;",
"   </p>",
"   <p>",
"    The pharmaceutical company that developed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/58/22437?source=see_link\">",
"     ivacaftor",
"    </a>",
"    plans to test its efficacy in CF subjects who have other mutations that affect CFTR channel activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/14\">",
"     14",
"    </a>",
"    ]. Unfortunately, when used alone, ivacaftor does not help patients who are homozygous for delta F508 (F508del), the most common CFTR mutation and one that causes abnormal CFTR protein folding that prevents its translocation to the apical cell membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/15\">",
"     15",
"    </a>",
"    ]. Studies are underway to determine if ivacaftor may have a potentiating effect when combined with investigational drugs designed to correct delta F508 folding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=see_link&amp;anchor=H3393787#H3393787\">",
"     \"Cystic fibrosis: Investigational therapies\", section on 'Combination strategy for the F508del mutation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of pulmonary disease in cystic fibrosis is characterized by chronic infections with multiple organisms, causing a gradual decline in pulmonary function, with periodic acute exacerbations heralded by symptoms such as increased sputum production and cough.",
"   </p>",
"   <p>",
"    At birth, the lungs of patients with CF are free of infection. Whether beginning in infancy or later in life, virtually all patients eventually develop repeated acute, viral, and bacterial infections that upregulate inflammation and lead to airway injury. Ineffective innate and acquired immunity ultimately results in a state of chronic bacterial infection.",
"   </p>",
"   <p>",
"    The onset and rate of chronic airway infection varies widely among patients due to differences in environmental influences (eg, primary or passive exposure to tobacco smoke, socioeconomic status), genetic effects (CFTR mutations and non-CFTR genetic modifiers), and medical interventions. Nonetheless, some patterns of infection can be observed: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link&amp;anchor=H2#H2\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Pathogens'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical microbiology laboratories identify Staphylococcus aureus as the most prevalent infecting bacteria in childhood; it continues to be a frequent pathogen throughout adulthood (",
"      <a class=\"graphic graphic_figure graphicRef74073 \" href=\"mobipreview.htm?18/0/18447\">",
"       figure 2",
"      </a>",
"      ). The portion of S. aureus that is methicillin resistant has been increasing. &nbsp;",
"     </li>",
"     <li>",
"      Haemophilus influenza is present in 20 to 30 percent of patients in childhood, but it becomes less prevalent in adults.",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa, which can be isolated in about 25 percent of infants, becomes the most frequently isolated bacteria in adults, reaching a prevalence rate of up to 80 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibiotics are essential tools for the treatment of both chronic infections and acute exacerbations of CF lung disease. Based on a few randomized trials, it appears that there is no advantage to scheduling elective periodic hospitalization and intravenous antibiotics for pulmonary toilet (\"clean-out\"), so this practice is now used infrequently in the United States, although it is variably embraced in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic treatment with oral antibiotics to control infection is not encouraged because the benefits have not outweighed the problems associated with antibiotic resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/18\">",
"     18",
"    </a>",
"    ] with two exceptions: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      is recommended for many patients with CF; its benefits may be due to its antiinflammatory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antibacterial properties. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Macrolide antibiotics'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Chronic treatment with nebulized antibiotics directed against Pseudomonas aeruginosa (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      ) appears to improve lung function and is recommended for many patients. These approaches are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link&amp;anchor=H16#H16\">",
"       \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Aerosolized antibiotics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BRONCHODILATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airflow obstruction is a central feature of CF lung disease, and is caused by several mechanisms. Impairment to flow is due to bronchial plugging by purulent secretions, bronchial wall thickening due to inflammation, and airway destruction. A subgroup of CF patients also have airflow obstruction from bronchial hyperreactivity; many, but not all, of these patients show typical signs and symptoms of asthma, such as chest tightness, wheezing, and cough following exercise or exposure to allergens or cold air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/19\">",
"     19",
"    </a>",
"    ]. Some of these patients are colonized with Aspergillus species and fulfill diagnostic criteria for allergic bronchopulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with CF demonstrate acute improvement in FEV1 following the administration of beta-adrenergic agonists, anticholinergic drugs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , regardless of the presence of typical asthmatic symptoms; the greatest improvements occur in those who have airway hyperreactivity and milder overall lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/19\">",
"     19",
"    </a>",
"    ]. In general, patients with severe airflow obstruction are less likely to show improvement, and a small number of patients show paradoxical reductions in airflow following inhalation of beta-adrenergic agonists.",
"   </p>",
"   <p>",
"    Despite the widespread use of bronchodilators in CF, few long-term studies have been performed to evaluate the chronic effects of bronchodilator treatment. One placebo-controlled crossover study of 27 patients found that one month of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    treatment improved peak flow measurements only in patients with a positive pretreatment bronchoprovocation study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    .) A comprehensive review of the literature concluded that beta-2 agonists have demonstrable efficacy only in this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate nonrandomized observational study found that FEV1 improved during a year of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    treatment, compared to a decline in FEV1 in a parallel population not taking the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/23\">",
"     23",
"    </a>",
"    ]. However, a subsequent placebo-controlled, double blind study in 21 patients failed to show that albuterol was superior to placebo, although the power to detect such a difference was low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/24\">",
"     24",
"    </a>",
"    ]. A randomized placebo controlled trial comparing albuterol with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    (100 mcg twice daily) showed better FEV1 percent predicted levels during treatment with salmeterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25485267\">",
"    <span class=\"h2\">",
"     Inhaled beta-2-adrenergic receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, we support the recommendations of a guidelines committee of the Cystic Fibrosis Foundation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"     26",
"    </a>",
"    ] who advise the regular use of inhaled beta-2-adrenergic receptor agonists in virtually all patients with CF. In practice, we recommend these agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    or a similar beta-2 adrenergic receptor agonist with rapid onset of action) for virtually all patients with CF, in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediately prior to sessions of chest physiotherapy and exercise to facilitate clearance of airway secretions. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chest physiotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Immediately prior to inhalation of nebulized hypertonic saline, antibiotics,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"       DNase",
"      </a>",
"      to limit nonspecific bronchial constriction induced by these agents and to potentially improve penetration and distribution of the drugs within the airways. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inhaled DNase I (dornase alfa)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is clinical evidence that chronic use of beta-2-adrenergic receptor agonist therapy increases expiratory flow rates in patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/21,25\">",
"     21,25",
"    </a>",
"    ]. This has led to the recommendation that clinicians prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    every four to six hours, or a long-acting beta-agonist (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ) every 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25485274\">",
"    <span class=\"h2\">",
"     Other bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-cholinergic agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide can induce bronchodilation following acute administration in patients with CF. Trials of the longer-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    are underway to determine its role in the chronic management of CF lung disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is infrequently prescribed in cystic fibrosis due both to the lack of proven efficacy and to its narrow therapeutic index and propensity to cause adverse gastrointestinal symptoms, tachycardia, and rarely seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     AGENTS TO PROMOTE AIRWAY SECRETION CLEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficulty clearing purulent secretions from the airways is a universal complaint from CF patients who have moderate to severe lung disease. Chemical analysis of CF sputum has shown that its high viscosity is caused by the interaction of several macromolecules, including mucus glycoproteins, denatured DNA, and protein polymers such as actin filaments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inhaled DNase I (dornase alfa)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endonuclease",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    I can decrease the viscosity of purulent CF sputum by cleaving long strands of denatured DNA that are released by degenerating neutrophils. The human DNase I gene has been cloned, and the protein that it encodes can help liquefy CF sputum. A randomized, blinded, placebo-controlled trial of 968 stable patients with an FVC &gt;40 percent of predicted values showed that the daily inhalation of 2.5 mg of nebulized DNase (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     dornase alfa",
"    </a>",
"    ) for six months resulted in a statistically significant improvement in FEV1 of approximately 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/29\">",
"     29",
"    </a>",
"    ]. A small but statistically significant reduction in the number of hospital days for exacerbations of respiratory disease was also seen in patients receiving the drug. Subsequent clinical trials have confirmed these findings and demonstrated benefit in children older than 6 years of age and with mild CF lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"     26",
"    </a>",
"    ]. A metaanalysis of randomized trials concluded that DNase treatment improves lung function and is well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients are generally treated daily; however, results from a 12-week cross-over trial of 48 patients found alternate day dosing of nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    resulted in equivalent clinical outcomes, and substantially lower drug costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. There is some variability among US CF centers in prescribing practices for DNase, probably influenced by the high cost of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/33\">",
"     33",
"    </a>",
"    ]. A guideline committee of the CF Foundation recommends the chronic use of DNase for all children with CF older than 6 years of age, regardless of symptoms or pulmonary function tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"     26",
"    </a>",
"    ]. Nebulized DNase is also suggested for infants and young children with CF with pulmonary symptoms, although this suggestion is based on inference from results in older age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/34\">",
"     34",
"    </a>",
"    ] and results of a small pilot study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/35\">",
"     35",
"    </a>",
"    ]. Our practice has been to offer it to all patients who have daily cough and to those with FEV1 below the normal range. We also begin chronic DNase if a patient's FEV1 drops below his or her baseline, even if it remains in the normal range, but fails to improve with treatment for an acute exacerbation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inhaled hypertonic saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertonic saline has been administered by inhalation to hydrate inspissated mucus that is present in the airways of patients with CF. It is presumed that the high osmolality of the solution draws water from the airway to re-establish the aqueous surface layer that is deficient in CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/36\">",
"     36",
"    </a>",
"    ]. The effectiveness of this strategy was shown by a study of 24 patients (&ge;14 years of age) with stable CF who were treated with 5 mL of 7 percent saline four times per day for 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/36\">",
"     36",
"    </a>",
"    ]. The mucus clearance rate was improved after 1 and 14 days of hypertonic saline treatment, and there were modest improvements in lung function and symptom scores. Parallel in vitro studies using cultured monolayers of airway epithelial cells showed that hypertonic saline caused sustained hydration of airway surfaces.",
"   </p>",
"   <p>",
"    The medium-term benefit of hypertonic saline was demonstrated by an Australian clinical trial in which 164 patients (&ge;6 years of age) with stable CF were randomly assigned to inhalation therapy with 4 mL of 7 percent saline or 0.9 percent saline following administration of a bronchodilator twice daily for 48 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/37\">",
"     37",
"    </a>",
"    ]. The study failed to show a statistically significant difference in its primary outcome, namely the rate of change in lung function during the 48 week trial. However, when averaged over the full duration of the study, lung function showed a small, statistically significant improvement in the hypertonic saline group. Patients treated with hypertonic saline had considerably fewer pulmonary exacerbations requiring antibiotic therapy (mean number of exacerbations per participant 0.39 versus 0.89) and fewer days absent from school or work or unable to participate in usual activities (7 versus 24 days). Treatment with hypertonic saline was not associated with worsening bacterial infection or inflammation. The treatment was well tolerated. A systematic review that included this study concluded that hypertonic saline has beneficial effects in patients &ge;six years of age with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, hypertonic saline cannot be considered to be part of the routine care of CF children under the age of six years. This was shown in a randomized clinical trial involving 344 subjects between 4 and 60 months of age (the ISIS trial), which failed to show clinical benefit of inhaling hypertonic saline (7 percent) compared to a control group receiving 0.9 percent saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/39\">",
"     39",
"    </a>",
"    ]. There was no benefit in the rate of pulmonary exacerbations (primary endpoint) or any of the secondary endpoints including a respiratory symptom score. As &ldquo;exploratory&rdquo; investigations in the ISIS study, infant pulmonary function tests including spirometry using the raised volume technique and lung volumes were performed on a subgroup of the subjects. Of these, only FEV0.5 showed a statistically significant improvement (38 mL) in the hypertonic saline group compared to controls. Given the exploratory nature of these tests, the FEV0.5 result can only be considered hypothesis-generating and not evidence of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/40\">",
"     40",
"    </a>",
"    ]. It has been suggested that the endpoints used in the ISIS trial may not have been adequately sensitive to detect clinically meaningful benefit in young patients with very mild pulmonary disease. Chest computed tomography, magnetic resonance imaging, and lung clearance index measurements are undergoing clinical investigations to determine if these are better modalities to detect early changes. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Additional studies are needed to refine the criteria for use of hypertonic saline in older patients with CF and optimal timing of treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/41\">",
"     41",
"    </a>",
"    ]. In a study of patient preference, the majority of patients favored inhaling hypertonic saline before or during their chest physiotherapy rather than after [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/42\">",
"     42",
"    </a>",
"    ]. Prescribing patterns vary greatly across CF centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/33\">",
"     33",
"    </a>",
"    ]. Our practice is to offer it to all patients six years of age and older who have chronic cough",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a mild reduction pulmonary function test results (eg, in FEV1) despite good compliance with the medical regimen. A convenient means to dispense hypertonic saline is now available through the CF Services Pharmacy (",
"    <a class=\"external\" href=\"file://www.cff.org/cf_services_pharmacy\">",
"     www.cff.org/cf_services_pharmacy",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     Albuterol",
"    </a>",
"    should be inhaled from a metered dose inhaler immediately prior to hypertonic saline administration to limit bronchospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Comparing the use of DNase and hypertonic saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open, crossover-design trial of 48 children receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    or hypertonic saline in 12-week blocks reported a significantly greater increase in FEV1 with DNase compared to hypertonic saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/31\">",
"     31",
"    </a>",
"    ]. In the previously mentioned large 48-week study of hypertonic saline, 38 percent of the subjects were also receiving DNase throughout the trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/37\">",
"     37",
"    </a>",
"    ]. Subgroup analysis revealed no difference in the beneficial effects of hypertonic saline between those receiving or not receiving DNase. However, the power of the study to detect clinically significant differences was not presented and probably was low.",
"   </p>",
"   <p>",
"    In the absence of well-designed comparison studies, the decision of when to prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    and hypertonic saline remains a conundrum. Because the mechanisms of action of DNase and hypertonic saline are different, their benefits may well be complementary. The guidelines committee of the CF Foundation addressed each treatment separately and recommended both for the majority of patients with CF without assigning priority of one over the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"     26",
"    </a>",
"    ]. We follow this recommendation but are frequently confronted with situations where a patient will not use both because of cost (DNase costs approximately 30-fold more than hypertonic saline), time required for administration (hypertonic saline is administered twice daily, and DNase once daily), tolerability (DNase typically is better tolerated than hypertonic saline in our experience), or general non-compliance.",
"   </p>",
"   <p>",
"    For patients willing and able to use both treatments, the following order of administration is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"     26",
"    </a>",
"    ]: (1)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    by metered dose inhaler, (2) hypertonic saline, (3) chest",
"    <span class=\"nowrap\">",
"     physiotherapy/exercise",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    in either order, and (4) other inhaled treatments such as aerosolized antibiotics. Inhaled medications should not be mixed together in the same nebulizer because the consequences of doing so are unknown. Of special note is DNase, which is inactivated when mixed with 7 percent saline. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chest physiotherapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inhaled N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-acetylcysteine, a free sulfhydryl reagent that cleaves disulfide bonds within mucus glycoproteins, can liquefy CF sputum in vitro. Although originally developed as an inhaled mucolytic agent, there are no well-designed studies that demonstrate its clinical utility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26,43\">",
"     26,43",
"    </a>",
"    ]. Furthermore, its potential to induce airway inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchospasm in a subgroup of patients and to inhibit ciliary function has led to reduction in its use. These deficiencies, in conjunction with its disagreeable odor, relatively high cost, and time required for administration cause us not to prescribe it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHEST PHYSIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retained purulent secretions are an important cause of airflow obstruction and airway injury in CF. In 1950, chest physiotherapy in the form of postural drainage and percussion was introduced to CF care and became the standard method to promote secretion clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/44\">",
"     44",
"    </a>",
"    ]. Increasingly, methods that can be performed without the aid of another person are replacing the traditional technique in older children and adults. These alternatives include a variety of breathing and coughing techniques such as \"autogenic drainage\", \"active cycle of breathing\", and \"huffing\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/45\">",
"     45",
"    </a>",
"    ]. Medical devices of varying cost and complexity have been developed to assist with airway clearance. These include airway oscillating devices, external percussion vests, and intrapulmonary percussive ventilation.",
"   </p>",
"   <p>",
"    Though practiced widely, there are relatively few high-quality clinical trials that evaluate the benefits of chest physiotherapy over extended periods of time. A year-long randomized trial studied the use of a \"PEP mask\", which contains a valve to generate positive expiratory pressure, and found that use of the device was associated with significant improvements in pulmonary function compared to postural drainage and percussion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/44\">",
"     44",
"    </a>",
"    ]. However, an examination of five Cochrane systematic reviews performed between 2000 and 2006 concluded there were insufficient data to assess the long-term effects of airway clearance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/46\">",
"     46",
"    </a>",
"    ]. Short-term trials suggested some benefit. No long-term studies show that one method of secretion clearance is superior to another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/47\">",
"     47",
"    </a>",
"    ]. An attempt to perform such a trial failed due to subject recruitment problems and high withdrawal rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/48\">",
"     48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Based upon available information, we recommend that all patients who produce sputum should be instructed in chest physiotherapy for secretion clearance. Adherence to chest physiotherapy is often poor, particularly among patients with mild disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Because patients vary in their acceptance and preference for different modes, several techniques should be introduced to each patient. Methods that can be performed without assistance from another person should be included to allow patients to have more control over their regimen. The cost of equipment should be considered, with less expensive modalities prescribed first. More expensive apparatus such as percussive vests may be appropriate for those patients who fail to clear secretions with less expensive methods, who report that the more expensive modalities are effective for them, and who remain compliant with their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with CF report that they mobilize secretions during aerobic exercise. One randomized, controlled trial of a three-year home exercise program was performed in children with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/51\">",
"     51",
"    </a>",
"    ]. Those assigned to the exercise arm of the study lost less forced vital capacity compared to the control group. The comparison of change in FEV1 showed the same trend (p &lt;0.07). In addition, one meta-analysis concluded that exercise with physiotherapy was superior to physiotherapy alone, but there is no evidence that exercise can substitute for airway clearance treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/46\">",
"     46",
"    </a>",
"    ]. Those with moderate or advanced disease should participate in organized pulmonary rehabilitation programs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=see_link\">",
"     \"Pulmonary rehabilitation in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTI-INFLAMMATORY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intense neutrophilic inflammation is a dominant pathological feature of the airways of patients with CF. Although the inflammatory response was formerly viewed as being necessary to prevent the spread of infection, increasing information indicates that the amount of inflammation developed is probably excessive and harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Macrolide antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrolide therapy was found to be beneficial for patients with panbronchiolitis, a non-CF lung disease that is seen predominantly in Japan and is manifested by bronchiectasis and chronic pseudomonas infection (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43769?source=see_link\">",
"     \"Diffuse panbronchiolitis\"",
"    </a>",
"    ). Clinicians caring for patients with CF began using macrolides empirically and their favorable observations prompted several well-constructed clinical trials of macrolides in CF.",
"   </p>",
"   <p>",
"    The largest clinical trial to date of macrolide therapy in CF studied 185 patients who were chronically infected with Pseudomonas aeruginosa and who had an FEV1 &gt;30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/53\">",
"     53",
"    </a>",
"    ]. Subjects were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    500 mg PO or placebo three days a week for 24 weeks. By the end of the trial, subjects taking azithromycin had a 4.4 percent improvement in percent predicted FEV1, although those receiving placebo had a 1.8 percent reduction; the difference was statistically significant. In addition, there were 40 percent fewer respiratory exacerbations in the azithromycin-treated group than in the control group. A subsequent report, which included patients with and without P. aeruginosa, concluded that even patients who did not demonstrate an improvement in lung function still derived benefit because of a decreased incidence of acute pulmonary exacerbations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/54\">",
"     54",
"    </a>",
"    ]. These results are in close agreement with three smaller studies that showed similar benefits from macrolides in patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/55-57\">",
"     55-57",
"    </a>",
"    ], and a one-year randomized trial in children with CF that revealed reductions in the frequency of pulmonary exacerbations and the need for additional antibiotics, although no change in FEV1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One placebo-controlled trial focused only on patients uninfected with P. aeruginosa, who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or placebo for 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/59\">",
"     59",
"    </a>",
"    ]. In this population of relatively healthy patients (mean FEV1 97 percent predicted), azithromycin did not improve lung function, as measured by FEV1. However, use of azithromycin was associated with clinically important improvements in several exploratory end points, including a 50 percent reduction in pulmonary exacerbations, 27 percent reduction in the initiation of new oral antibiotics (other than azithromycin), 0.58 kg weight gain, and 0.34 unit increase in BMI. There were no differences in treatment groups in use of intravenous or inhaled antibiotics or hospitalizations.",
"   </p>",
"   <p>",
"    A systematic review that included all of the above studies concluded that six months of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    improves respiratory function in patients with CF and reduces the frequency of pulmonary exacerbations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms by which macrolides improve CF lung disease are uncertain and may involve direct effects on infecting bacteria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suppression of the excessive inflammatory response seen in the CF lung. Macrolides are unable to kill pseudomonas bacteria that are grown under conditions routinely used in clinical microbiology laboratories. However, macrolides have microbicidal activity against pseudomonas bacteria that are grown under conditions that induce biofilm formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/61\">",
"     61",
"    </a>",
"    ]. Furthermore, macrolides can block quorum sensing and reduce the ability of pseudomonas to produce biofilms, which is considered one of the mechanisms by which the bacteria avoid being killed by traditional antipseudomonal antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/62\">",
"     62",
"    </a>",
"    ]. Independent of their effect on bacteria, there is mounting evidence that macrolides may be beneficial in CF lung disease by suppressing the excessive inflammatory response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we recommend using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    for all patients with CF older than six years of age regardless of P. aeruginosa infection status who have clinical evidence of airway inflammation such as chronic cough, or who have any reduction in FEV1. The guidelines published by the CF Foundation do not restrict the use of azithromycin to those with evidence of airway inflammation or reduction in FEV1 as we suggest here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"     26",
"    </a>",
"    ]. However, because of limited data on the safety of prolonged use of azithromycin, we recommend delaying its routine use in patients who have negligible evidence of airway disease and whose expected benefit may be minimal. We usually prescribe the medication three times a week, using 250 mg for patients with body weight less than 40 kg, and 500 mg for those over 40 kg. A study in adults shows that 250 mg daily is similarly efficacious, so daily dosing could be used for those patients who find it easier to adhere to a daily treatment schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/57\">",
"     57",
"    </a>",
"    ]. For the small number of patients who develop gastrointestinal side effects on full dose, a lower dose may be used (eg, 250 mg three times a week for adult-sized patients); this dose reduction was employed in one study and was thought to be of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to initiating treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , we recommend that a sputum specimen be examined for nontuberculous mycobacteria; macrolide therapy should NOT be initiated if nontuberculous mycobacteria are present. This is because macrolides are an important component of treatment regimens for M. avium complex infection and should be used only as part of a multi-drug regimen, to avoid development of macrolide resistant mycobacterial species. If smear-negative patients are subsequently positive by culture, the macrolide should be stopped to avoid induction of macrolide resistance. The decision to treat nontuberculous mycobacteria with multiple antibiotics should be based on an assessment of the likelihood that the mycobacteria are causing tissue injury and clinical deterioration, and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ibuprofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the recognition that anti-inflammatory glucocorticoids reduce the rate of FEV1 decline in CF,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    was studied to determine if similar benefits could be obtained without the prohibitive side effects of glucocorticoids. The clinical value of high-dose ibuprofen was demonstrated in two long-term studies in patients with mild CF lung disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      was conducted in 85 individuals 5 to 39 years old with mild disease. Repeated pharmacokinetic studies were performed on study subjects to ensure that high-peak blood levels of ibuprofen (50 to 100",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      were obtained [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/65\">",
"       65",
"      </a>",
"      ]. After four years, patients in the ibuprofen group who completed the study lost only 1.5 percent of their predicted FEV1 per year, compared to a loss of 3.6 percent of predicted FEV1 per year for the control group. However, the beneficial effects of ibuprofen were seen only in the subgroup of patients who were younger than 13 years of age at the start of the study. Gastrointestinal bleeding and renal impairment, known adverse effects of ibuprofen, were not observed in either group.",
"     </li>",
"     <li>",
"      In a multicenter randomized trial, a similar protocol was tested in 142 patients 6 to 18 years old [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/66\">",
"       66",
"      </a>",
"      ]. The primary outcome of this study, rate of decline in FEV1 percent predicted, was not statistically reduced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      as compared to placebo. However, the study did not meet its recruitment targets, causing it to be underpowered to detect a difference of 2 percent. The group treated with ibuprofen did show a statistically significant reduction in the rate of decline of FVC percent predicted (0.07 &plusmn; 0.51 versus -1.62 &plusmn; 0.52), which was a secondary endpoint of the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines committee of the CF Foundation suggests the use of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    in children older than 6 years of age who have good lung function (FEV1 &gt;60 percent predicted) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the evidence supporting this treatment is still limited, and concerns remain about the potential long-term effects on renal function. We do not recommend initiation of ibuprofen after the age of 13 years because of lack of any proof of efficacy in this population. If high-dose ibuprofen is prescribed, pharmacokinetic studies should be performed periodically to ensure correct dosing, and patients should be monitored closely for the development of adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In practice, high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is being prescribed for only a small minority of pediatric-aged patients in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/33\">",
"     33",
"    </a>",
"    ]. The requirement for periodic pharmacokinetic adjustment of the dose and concern for side effects appear to be restricting its acceptance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the theory that excessive inflammation may be a contributor to lung damage in CF, systemic glucocorticoids have been investigated for their anti-inflammatory effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chronic administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1985, the results of a randomized, placebo-controlled study of glucocorticoids in children with CF were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/68\">",
"     68",
"    </a>",
"    ]. After 40 months of treatment, the group receiving 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    every other day had higher values of FEV1 and fewer hospitalizations for pulmonary disease compared to the placebo group. Adverse effects from the prednisone were minimal. These observations spawned a larger multi-center study testing every other day prednisone (either 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    against placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/69\">",
"     69",
"    </a>",
"    ]. The high-dose arm of the study was halted early because of an unacceptably high incidence of abnormal glucose metabolism, cataracts, and growth failure. Long-term follow up of this trial revealed that boys treated with prednisone had significant reductions in adult height as compared with those treated with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/70\">",
"     70",
"    </a>",
"    ]. Among girls, the long-term effects of prednisone on height were not statistically significant. Similar but milder changes were seen in the lower-dose prednisone group when data were analyzed at the planned conclusion of the trial.",
"   </p>",
"   <p>",
"    We agree with the guidelines committee of the CF Foundation, which recommends against the routine chronic use of oral corticosteroids for children with CF aged 6 to 18 years, in the absence of asthma or allergic bronchopulmonary aspergillosis, because of the associated adverse effects. The committee found insufficient data on which to judge the value of chronic glucocorticoids in adults. Because of concerns about the increased susceptibility of CF patients to glucocorticoid-induced hyperglycemia and osteoporosis in addition to the other complications of long-term treatment with corticosteroids, we also do not recommend chronic oral corticosteroids to patients in the adult age group, unless needed for concomitant asthma or allergic bronchopulmonary aspergillosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Short-term treatment for acute pulmonary exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids have established benefits in acute exacerbations of non-CF COPD, prompting some clinicians to use them for acute exacerbations in patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10360?source=see_link\">",
"     \"Role of systemic glucocorticoid therapy in COPD\"",
"    </a>",
"    .) A pilot study evaluated this practice in a randomized, double blind, placebo controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/72\">",
"     72",
"    </a>",
"    ]. Twenty-four patients with CF and an acute pulmonary exacerbation were treated with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 2",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    (maximum 60 mg) or placebo for five days. The primary endpoint, the rate of improvement in FEV1 from days one to six, did not differ significantly between groups, although the power of the study to detect differences was small. None of the secondary endpoints showed a statistically significant difference. Using the data from this pilot study, the investigators concluded that more than 250 patients would need to be entered to detect a 4 percent improvement in FEV1 percent predicted.",
"   </p>",
"   <p>",
"    In practice, we use systemic glucocorticoids during acute pulmonary exacerbations only for those patients with predominant asthma-like symptoms, eg, those with prominent sensation of chest tightness, minimal expectoration of sputum despite mucus plugging on chest x-ray, documented response to bronchodilator in the pulmonary function laboratory, and high-pitched wheezes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor air movement by auscultation. For these patients, we use 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (maximum of 40 to 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and restrict the duration to approximately five days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids have been prescribed in an effort to obtain the benefits that were demonstrated in the oral glucocorticoid trials while reducing the adverse effects of oral therapy. However, only a few studies have evaluated their effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 55 patients with CF but without clinically evident asthma to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (800 mcg) or placebo twice daily for three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/73\">",
"       73",
"      </a>",
"      ]. Deterioration of lung function (measured by the FEV1) was less in the budesonide group, suggesting that inhaled glucocorticoids are beneficial in this subset of CF patients.",
"     </li>",
"     <li>",
"      In contrast, two randomized, controlled trials of 49 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/74\">",
"       74",
"      </a>",
"      ] and 12 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/75\">",
"       75",
"      </a>",
"      ] failed to demonstrate any benefit of inhaled glucocorticoids on the FEV1 in unselected CF patients.",
"     </li>",
"     <li>",
"      In a larger placebo-controlled trial, 171 patients who were receiving inhaled glucocorticoids at study entry were randomly assigned to either continue or stop treatment for six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/76\">",
"       76",
"      </a>",
"      ]. An additional 31 subjects who were otherwise eligible for the study were excluded by their clinicians, usually because they had signs and symptoms suggesting a significant asthmatic component to their CF lung disease. Cessation of glucocorticoids had no impact on the duration until the first exacerbation, lung function, antibiotic use, or bronchodilator use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it seems reasonable to continue prescribing aerosolized glucocorticoids to CF patients who have definite signs and symptoms of asthma or allergic bronchopulmonary aspergillosis, there is insufficient evidence to warrant broader use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/77\">",
"     77",
"    </a>",
"    ]. We agree with the guidelines committee of the CF Foundation, which recommends against their routine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/34\">",
"     34",
"    </a>",
"    ]. One of the reasons for caution is that inhaled glucocorticoids may modestly impair linear growth in children with CF or asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. These effects are dose-related and less severe than those seen in children treated with systemic glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cromolyn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium cromoglycate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    are anti-inflammatory drugs that have been used for the treatment of asthma; nedocromil is no longer available in the United States. Neither has been studied adequately in patients with CF. The few small studies that have been performed detected no benefit or adverse effects. As an example, one double-blind, placebo-controlled, crossover study was performed on 14 patients with cystic fibrosis and bronchial hyperreactivity; no improvement in clinical status or pulmonary function tests was seen among patients receiving sodium cromoglycate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the lack of adequate studies of cromolyn in patients with CF, the relatively high expense, and the evidence of inferiority relative to inhaled glucocorticoids in patients with asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/81\">",
"     81",
"    </a>",
"    ], we do not prescribe cromoglycate or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    for our patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     VACCINATIONS AND PALIVIZUMAB",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral respiratory infections have been implicated as a frequent cause of exacerbations of CF lung disease (reviewed in [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/34,82,83\">",
"     34,82,83",
"    </a>",
"    ]). Based on efficacy in other populations, annual vaccination against viral influenza is recommended for all patients with CF older than 6 months of age, using an inactivated vaccine delivered by injection, but not the live attenuated vaccine delivered by intranasal spray. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pneumococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pneumococcal vaccine is recommended for all patients with CF because of a favorable risk-benefit profile, although Streptococcus pneumoniae is not a major cause of pulmonary exacerbations in CF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Palivizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40371?source=see_link\">",
"     palivizumab",
"    </a>",
"    , a humanized monoclonal antibody against respiratory syncytial virus for children younger than 24 months of age, have suggested possible efficacy in CF, but definitive studies have not been performed, preventing firm recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38327?source=see_link\">",
"     \"Respiratory syncytial virus infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUPPLEMENTAL OXYGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive cystic fibrosis is routinely accompanied by worsening hypoxemia. However, there is little information about the effect of supplemental oxygen on the course of the disease. The use of short-term oxygen therapy during sleep and exercise was evaluated in a systematic review of nine small, randomized, controlled trials of patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/85\">",
"     85",
"    </a>",
"    ]. Supplemental oxygen during exercise was associated with improved exercise duration and peak performance. Use of nocturnal oxygen did not improve qualitative sleep parameters.",
"   </p>",
"   <p>",
"    Only one of the studies in the systematic review examined long-term oxygen therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/86\">",
"     86",
"    </a>",
"    ]. No statistically significant improvement in survival, lung function, or cardiac health was detected. In addition, improvement of oxygenation was accompanied by modest but probably clinically inconsequential hypercapnia.",
"   </p>",
"   <p>",
"    Until larger, controlled trials exist, we recommend supplemental oxygen for patients with CF to treat intermittent or chronic hypoxemia. We believe it is appropriate to assume that supplemental oxygen will delay or ameliorate the complications of chronic hypoxemia in CF, as it does in chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/6\">",
"     6",
"    </a>",
"    ]. In the absence of studies examining oxygen use in patients with CF, we follow the same recommendations for use as in patients with COPD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NONINVASIVE POSITIVE PRESSURE VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (BiPAP) has been used for patients with advanced cystic fibrosis lung disease and hypercapnia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In a randomized trial in adults with daytime hypercapnia, nocturnal use of BiPAP was compared to supplemental oxygen or placebo (air). Six weeks of BiPAP improved chest symptoms, exertional dyspnea, nocturnal hypoventilation, and peak exercise capacity, without measurable improvement in lung function. Based on these studies, it would be appropriate to offer nocturnal noninvasive BiPAP to patients whose arterial carbon dioxide level remains elevated (eg, &ge;50 mmHg) despite maximizing other treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INTENSIVE CARE UNIT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes for CF patients requiring treatment in an intensive care unit was previously reported to be uniformly poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/89\">",
"     89",
"    </a>",
"    ], but has fortunately improved. In modern series, survival was dependent upon the severity of respiratory failure, with the best outcomes for those who could be managed by noninvasive ventilation and the worst for those requiring endotracheal",
"    <span class=\"nowrap\">",
"     intubation/ventilation",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/90-95\">",
"     90-95",
"    </a>",
"    ]. Most of these studies were of adult CF patients, but one included five children who were less than two years old, all of whom survived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/94\">",
"     94",
"    </a>",
"    ]. There are probably multiple reasons for the improved outcomes, including the use of non-invasive ventilation to sustain the patient until other measures to reverse the respiratory failure take effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the long-term prognosis following an episode of respiratory failure is still poor in older children and adults, intensive care unit support appears to be particularly useful for those patients who are candidates for lung transplantation. In addition, intubation and positive pressure ventilation are indicated for infants and young children with acute bronchiolitis but without extensive bronchiectasis, especially in the context of a documented acute viral infection.",
"   </p>",
"   <p>",
"    An episode of respiratory failure, regardless of age (except for infants and young children with pure bronchiolitis), should prompt discussion of end-of-life care, quality of life, and the possible indications for lung transplantation, if and when extubation occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LUNG TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advancements in the treatment of CF lung disease have delayed but not arrested disease progression; premature death from respiratory failure still occurs in the majority of patients. As in other progressive lung diseases, lung transplantation provides an additional, albeit imperfect, management option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/97-100\">",
"     97-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually all lung transplants for patients with CF require replacing both lungs, because leaving a native lung in place would present a huge source of infected secretions that would threaten the transplanted lung. A registry compiled by the International Society for Heart and Lung Transplantation reports that 758 lung transplants were performed in children with CF from January 2000 to June 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/101\">",
"     101",
"    </a>",
"    ], and 4161 transplants were performed in adults with CF from January 1995 to June 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Timing of transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for referral to a lung transplant center are driven by estimates of a patient's predicted survival and quality of life with and without lung transplant. A retrospective study using data from the CF Foundation Registry concluded that transplantation extends life if performed when the patient has a five-year predicted survival without transplant of less than 30 percent, and possibly when the predicted survival is less than 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/103\">",
"     103",
"    </a>",
"    ]. A means to calculate the survival likelihood was provided. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Based on a consensus report from the International Society for Heart and Lung Transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/104\">",
"     104",
"    </a>",
"    ], we recommend that a patient should be referred to a transplant center when any of the following indications are present: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      FEV1 below 30 percent predicted or a rapid decline in FEV1, particularly in young female patients",
"     </li>",
"     <li>",
"      Increasing frequency of exacerbations requiring antibiotic therapy",
"     </li>",
"     <li>",
"      Refractory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent pneumothorax",
"     </li>",
"     <li>",
"      Recurrent hemoptysis not controlled by embolization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since 2005, in the United States, the position of each individual lung transplant candidate on the priority list for transplant is determined by a lung allocation score formulated by UNOS (United Network for Organ Sharing). The score is based on lung diagnosis, age, body mass index, diabetes, supplemental oxygen use, six-minute walk distance, pulmonary artery systolic pressure, pulmonary capillary wedge pressure, serum creatinine functional status, and need for assisted ventilation. Details about the scoring system are available from the Organ Procurement and Transplantation Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/105\">",
"     105",
"    </a>",
"    ]. Because the number of lungs available for transplantation is insufficient for the number of patients needing them, the timing of when a patient receives lungs is determined more by when they become sick enough to reach the top of the priority list rather than when they are referred for transplant evaluation. There are wide variations in the length of waiting lists among transplant centers and individual patients may be served by exploring a number of different lung transplant centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each transplant center has its own list of relative and absolute contraindications for lung transplantation. In addition to the general contraindications for lung transplantation applicable for all disease indications, there are several CF-specific considerations. Chronic infection with Burkholderia cenocepacia connotes a worse prognosis following transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/106-109\">",
"     106-109",
"    </a>",
"    ]. Most, but not all, transplant centers consider infection with this organism to be a contraindication to the procedure. Other species of Burkholderia do not appear to have the same adverse effects, with the possible exception of B. gladioli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/106-109\">",
"     106-109",
"    </a>",
"    ]. Patients infected with multidrug-resistant Pseudomonas aeruginosa have slightly worse survival following lung transplant compared to those infected with drug-sensitive P. aeruginosa, but the decrement is minor; their survival is similar to that of patients undergoing lung transplantation for non-CF diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Outcomes'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31192?source=see_link\">",
"     \"Lung transplantation: Disease-based choice of procedure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most lung transplant centers in the United States will not accept the referral of intubated patients in acute respiratory failure for lung transplant evaluation. The survival of these patients without transplantation is poor, and prolonged ICU stays are associated with progressive deconditioning of affected individuals, another strong contraindication to transplantation in many centers. In addition, their poor clinical status prohibits education and informed consent of the patient, who is expected to adhere to a post-transplant regimen that is complex and can be onerous.",
"   </p>",
"   <p>",
"    Symptomatic osteoporosis is a relative contraindication for lung transplantation in general, but it takes on special significance for patients with CF. The frequency of osteoporosis in CF increases with age and affects about 20 percent of individuals in the 18- to 25-year age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, pre-symptomatic diagnosis and treatment of",
"    <span class=\"nowrap\">",
"     osteopenia/osteoporosis",
"    </span>",
"    is important to avoid exclusion of a patient from consideration for transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CF who undergo lung transplantation have better survival rates compared with those of patients who are transplanted for other disease indications (",
"    <a class=\"graphic graphic_figure graphicRef65977 \" href=\"mobipreview.htm?16/59/17342\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=see_link\">",
"     \"Lung transplantation: An overview\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The benefits of lung transplantation in CF have been assessed using retrospective data from the CF Foundation Registry. Outcomes for 458 patients who underwent lung transplantation for CF between 1992 and 1998 were compared to those of 11,630 patients who did not undergo transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/103\">",
"     103",
"    </a>",
"    ]. The following observations regarding transplantation and survival were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with predicted five-year survival of less than 30 percent, lung transplantation is associated with a clear improvement in survival.",
"     </li>",
"     <li>",
"      Survival benefit was equivocal for patients with a predicted five-year survival of 30 to 50 percent.",
"     </li>",
"     <li>",
"      Patients with predicted five-year survival of greater than 50 percent and who underwent transplantation (though few in number) had a lower rate of survival than their nontransplanted counterparts.",
"     </li>",
"     <li>",
"      The benefit of transplantation also varied with time. Overall survival was superior in nontransplanted controls during the first 2.5 years of follow-up; however, after four years transplanted patients demonstrated increased survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An analysis of 514 pediatric aged patients who were listed for lung transplantation between 1992 and 2002 was performed by the same research group using merged data from the CF Foundation Registry and the Organ Procurement and Transplantation Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/112\">",
"     112",
"    </a>",
"    ]. This study failed to show a definite survival advantage, except for a small minority of transplanted patients who were younger than 18 years of age at the time of listing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/112\">",
"     112",
"    </a>",
"    ]. This contradicts a previous report from the United Kingdom that found a survival advantage for transplanted children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/113\">",
"     113",
"    </a>",
"    ]. After correcting for multiple potential risk factors, the older study reported that the hazard ratio for death in the transplanted group was 0.31 (95% Cl 0.13-0.72, p = 0.007).",
"   </p>",
"   <p>",
"    Reasons for the discrepancy described above are the subject of active debate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/114\">",
"     114",
"    </a>",
"    ]. It is possible that the worse survival for transplanted pediatric CF patients compared to those on the wait list in the US study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/112\">",
"     112",
"    </a>",
"    ] may be an artifact of the method by which patients were prioritized for transplantation. Specifically, the data in the US study were collected at a time when transplant priority was based upon time spent on the waiting list. This induced clinicians to list patients early so that they had a very good chance of surviving long enough to accrue the two or more years that were sometimes necessary to reach the top of the list. The current lung allocation system places no premium on how long the patient is on the list for all individuals 12 years and older. Instead, it distributes donor lungs to those with the greatest predicted increase in one-year survival after transplantation.",
"   </p>",
"   <p>",
"    Subsequent studies from experienced centers have reported five-year survival rates around 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/99,115\">",
"     99,115",
"    </a>",
"    ]. These investigators argue that transplantation does indeed improve survival as compared with estimated five-year survival in non-transplanted patients. Because of limited numbers of patients in the pediatric age group, these studies were unable to draw definitive conclusions regarding this subgroup. However, Cox regression analysis detected no adverse effect of age &lt;18 years on survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Limitations of transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many problems remain after lung transplantation for CF. The procedure does not address the non-pulmonary problems associated with CF. Chronic sinusitis, cirrhosis, cholelithiasis, pancreatic insufficiency, CF-associated diabetes mellitus, osteoporosis, and distal intestinal obstruction syndrome remain causes of morbidity and occasionally of mortality. Pancreatic insufficiency and abnormalities in bowel motility can make",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    absorption and dosing difficult; glucocorticoid treatment to suppress graft rejection complicates diabetic management and accelerates osteoporosis. Studies examining quality of life after lung transplantation for CF generally show improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. Most children return to school and many adults return to work.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2009, there were 226 pregnancies reported in the CF Foundation Registry, which is a rate of 1.6 live births per 100 women in a reproductive age range. Small case series and larger cohort studies have not documented adverse maternal outcomes for women with mild to moderate pulmonary disease (ie, FEV1 &gt;60 percent predicted) who become pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/119-124\">",
"     119-124",
"    </a>",
"    ]. Severe lung disease, especially when pulmonary hypertension is present, is a bad prognostic indicator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/124\">",
"     124",
"    </a>",
"    ], although successful outcomes have been reported in a few women who had severe impairment of lung function prior to conception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies report an increased rate of premature delivery for pregnancies in women with cystic fibrosis (around 25 percent, range 5 to 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/124-127\">",
"     124-127",
"    </a>",
"    ]), but the rate of spontaneous abortion is not increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/128\">",
"     128",
"    </a>",
"    ]. Breastfeeding is not contraindicated, although there has been one report of hypernatremic colostrum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general principles of pregnancy management for women with cystic fibrosis include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/130\">",
"     130",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Achieving optimal, stable pulmonary function prior to conception and carefully monitoring during pregnancy",
"     </li>",
"     <li>",
"      Providing genetic counseling regarding the risk of disease in offspring, carrier testing of the father, and options for prenatal diagnosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22503?source=see_link\">",
"       \"Cystic fibrosis: Prenatal genetic screening\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Close monitoring maternal nutrition and weight gain",
"     </li>",
"     <li>",
"      Screening for gestational diabetes early in pregnancy because of the increased risk for secondary insulin deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     NONINFECTIOUS PULMONARY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous pneumothorax and hemoptysis are well-recognized complications of CF, particularly among adults. These complications have become increasingly common as overall survival continues to improve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/131,132\">",
"     131,132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Spontaneous pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous pneumothorax occurs in 3 to 4 percent of patients with cystic fibrosis during their lifetime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/131\">",
"     131",
"    </a>",
"    ]. Major risk factors are older age and more severe obstructive lung disease. Treatment of pneumothorax in CF patients does not differ from that of patients with other types of lung disease (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40793?source=see_link\">",
"     \"Spontaneous pneumothorax in children\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Guidelines have been published for the management of pneumothorax in patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/133\">",
"     133",
"    </a>",
"    ]. Pleurodesis when needed to address persistent air leaks or other pleural space problems should not preclude subsequent lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. However, avoidance of more aggressive pleural stripping procedures or the use of talc may be advisable to reduce subsequent bleeding complications if and when the native lungs are removed at transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/136\">",
"     136",
"    </a>",
"    ]. Collaboration between the consulting CF Center surgeon and a lung transplant surgeon is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Hemoptysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor hemoptysis is a common occurrence in patients with cystic fibrosis, particularly during pulmonary exacerbations. Other than assuring that vitamin K deficiency is not a contributing factor, it requires no special treatment beyond the usual approach for the exacerbation. However, even minor hemoptysis can be alarming to patients and reassurance as to its usually benign nature is needed.",
"   </p>",
"   <p>",
"    Massive hemoptysis is defined as acute bleeding of more than 240 mL within 24 hours, or recurrent bleeding of more than 100 mL daily for several days. This occurs in approximately 1 percent of patients each year with the major risk factors being age and worse pulmonary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/132\">",
"     132",
"    </a>",
"    ]. Management guidelines generated by a panel of experts have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/133\">",
"     133",
"    </a>",
"    ]. The guidelines recommend suspension of all chest physiotherapy in the event of massive hemoptysis. Consensus could not be reached for use of aerosolized medications for massive hemoptysis. Other than maximizing treatment as one would for a severe pulmonary exacerbation, the management of massive hemoptysis in CF does not otherwise differ from that of hemoptysis in other patients with bronchiectasis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    has been used successfully in several case reports. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37896?source=see_link&amp;anchor=H21#H21\">",
"     \"Hemoptysis in children\", section on 'Hemostasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of registry data collected by the CF Foundation shows moderate variability in the clinical outcomes and treatment approaches across the 115 CF Centers within the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/137\">",
"     137",
"    </a>",
"    ]. After correcting for adverse risk factors that differ between centers such as patient age and socioeconomic status, a conservative estimate is that median survival in CF could be improved by at least several years if best practices could be identified and implemented across all CF Centers. On the other hand, there is no question that individually tailored therapies by experienced clinicians will remain equally important in the management of these complex patients. In response to knowledge and a strong endorsement from the CF Foundation, an intensive quality",
"    <span class=\"nowrap\">",
"     assessment/quality",
"    </span>",
"    improvement program is ongoing in all CF Centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/22/39274/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A wide variety of new treatment strategies are being investigated for CF (see",
"    <a class=\"external\" href=\"file://www.cff.org/treatments/Pipeline/\">",
"     www.cff.org/treatments/Pipeline/",
"    </a>",
"    ). They span a wide range of approaches that include (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=see_link\">",
"     \"Cystic fibrosis: Investigational therapies\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gene therapy",
"     </li>",
"     <li>",
"      Correction of abnormal protein folding that is induced by many of the more prevalent CFTR mutations",
"     </li>",
"     <li>",
"      Improvement in ion channel function of various mutant CFTR proteins",
"     </li>",
"     <li>",
"      Drugs to induce ribosomes to selectively read through premature CFTR stop codons",
"     </li>",
"     <li>",
"      Induction of alternative ion channels",
"     </li>",
"     <li>",
"      Suppression of excessive inflammatory responses",
"     </li>",
"     <li>",
"      Development of alternative delivery methods for antibiotics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of the promising investigational therapies that have reached the stage of clinical trials are discussed in a separate topic review. Successful completion of even a subset of these investigations should serve to continue the trend of improved survival in CF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=see_link\">",
"     \"Cystic fibrosis: Investigational therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20371?source=see_link\">",
"       \"Patient information: Cystic fibrosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/57/40850?source=see_link\">",
"       \"Patient information: Bronchiectasis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following treatment recommendations apply to children 6 years of age and older unless otherwise specified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic fibrosis lung disease typically has a course of intermittent acute exacerbations, superimposed on a gradual decline in pulmonary function. Exacerbations are treated with antibiotics, given either orally, via inhalation, or intravenously, depending on the infecting organisms and the severity of the exacerbation. The role of antibiotics in the treatment of cystic fibrosis lung disease is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link\">",
"       \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All patients with cystic fibrosis should undergo CFTR genotyping to determine if they carry a G551D mutation in their CFTR genes. Because this mutation was identified in 1990, it is highly likely that most CF patients who were genotyped after the early 1990s would have G551D identified if it was present. (See",
"      <a class=\"local\" href=\"#H20592751\">",
"       'CFTR modulators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with cystic fibrosis who carry at least one copy of the G551D mutation and are six years of age or older, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/58/22437?source=see_link\">",
"       ivacaftor",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Ivacaftor is given at a dose of 150 mg by mouth every 12 hours with fat-containing foods. (See",
"      <a class=\"local\" href=\"#H20592751\">",
"       'CFTR modulators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using short-acting inhaled beta-2-adrenergic receptor agonists for patients with CF prior to inhalation of hypertonic saline, antibiotics, or initiating chest physiotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest chronic use of these agents if there is evidence that they improve expiratory flow rates in those with baseline airflow obstruction (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Bronchodilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend chronic treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"       DNase",
"      </a>",
"      I (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"       dornase alfa",
"      </a>",
"      ) for children with moderate to severe cystic fibrosis lung disease (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also suggest treatment for patients with mild or asymptomatic lung disease, but the quality of evidence and likely clinical benefit are lower for this group (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inhaled DNase I (dornase alfa)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend chronic treatment with hypertonic saline via nebulizer for patients six years and older who have a chronic cough and any reduction in FEV1 (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also suggest it may be of benefit for patients in this age group with milder disease manifestations (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A typical treatment regimen is 4 mL of 7 percent saline following administration of a bronchodilator twice daily. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inhaled hypertonic saline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all patients who produce sputum be treated with a form of physiotherapy for mucus clearance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This suggestion is based on demonstrated benefits to secretion clearance with the use of a variety of methods of physiotherapy, including aerobic exercise. However, it should be recognized that long-term improvement in clinical outcome has not been shown, and any clinical benefits must be weighed against the potential treatment burden for the patient. Because patients vary in their responses to different modes, several techniques should be introduced to each patient. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chest physiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the chronic use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      for patients six years and older who have clinical evidence of airway inflammation such as chronic cough, or any reduction in FEV1, regardless of the patient&rsquo;s P. aeruginosa infection status (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). To avoid induction of antibiotic resistance, azithromycin should not be given to patients infected with nontuberculous mycobacteria. This drug slows decline of lung function, likely through antiinflammatory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antibacterial effects. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Macrolide antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      in children and young adolescents with good lung function (&gt;60 percent predicted) in whom there is no contraindication to this therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The evidence base for this practice is limited to a few studies, and there is inadequate evidence to support this suggestion for adult patients or for patients with poor lung function. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Ibuprofen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CF but without asthma or allergic bronchopulmonary aspergillosis, we recommend AGAINST treating with inhaled corticosteroids (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). For this group, there are no clear benefits, and the treatment may impair linear growth. For patients with CF and asthma, inhaled corticosteroids have greater clinical benefit, and the treatment may be considered along with other anti-asthmatic treatments. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children and adolescents with CF, we recommend AGAINST chronic treatment with systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although there is a slight benefit to lung function, these do not outweigh the adverse effects on growth, glucose metabolism, and cataract risk for most patients. In adults, we also suggest AGAINST chronic treatment with systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of supplemental oxygen to treat chronic hypoxemia has not been studied in patients with cystic fibrosis. In the absence of such evidence, it is reasonable to extrapolate from the benefits demonstrated for this treatment for patients with COPD and to apply the same indications for its chronic use. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Supplemental oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe cystic fibrosis lung disease is a common indication for lung transplantation, and outcomes are better than those of patients undergoing lung transplantation for other indications. Chronic infection with Burkholderia cenocepacia connotes a worse prognosis following transplantation and is often considered a contraindication to the procedure. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/1\">",
"      Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/2\">",
"      Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med 2007; 28:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/3\">",
"      O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/4\">",
"      Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009; 54:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/5\">",
"      Goss CH, Rosenfeld M. Update on cystic fibrosis epidemiology. Curr Opin Pulm Med 2004; 10:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/6\">",
"      Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/7\">",
"      Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998; 316:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/8\">",
"      Johnson C, Butler SM, Konstan MW, et al. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003; 123:20.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. FDA approves Kalydeco to treat rare form of cystic fibrosis. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/10\">",
"      Davis PB. Therapy for cystic fibrosis--the end of the beginning? N Engl J Med 2011; 365:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/11\">",
"      Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009; 106:18825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/12\">",
"      Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663.",
"     </a>",
"    </li>",
"    <li>",
"     Press release, Vertex pharmaceuticals 11/3/2011. Available at: file://investors.vrtx.com/releasedetail.cfm?ReleaseID=620643 (Accessed on February 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/14\">",
"      Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11:237.",
"     </a>",
"    </li>",
"    <li>",
"     Manufacturer's prescribing information, Kalydeco (ivacaftor) tablets, section 14.2 (p. 9). Available at: file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203188lbl.pdf (Accessed on February 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/16\">",
"      Elborn JS, Prescott RJ, Stack BH, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/17\">",
"      Nir M, Lanng S, Johansen HK, Koch C. Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre. Thorax 1996; 51:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/18\">",
"      Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2012; 7:CD002767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/19\">",
"      Weinberger M. Airways reactivity in patients with CF. Clin Rev Allergy Immunol 2002; 23:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/20\">",
"      Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 Suppl 3:S225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/21\">",
"      Eggleston PA, Rosenstein BJ, Stackhouse CM, et al. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991; 99:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/22\">",
"      Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev 2005; :CD003428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/23\">",
"      K&ouml;nig P, Gayer D, Barbero GJ, Shaffer J. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatr Pulmonol 1995; 20:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/24\">",
"      K&ouml;nig P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol 1998; 25:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/25\">",
"      Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 2002; 34:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/26\">",
"      Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/27\">",
"      Shak S. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest 1995; 107:65S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/28\">",
"      Vasconcellos CA, Allen PG, Wohl ME, et al. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/29\">",
"      Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/30\">",
"      Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2010; :CD001127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/31\">",
"      Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/32\">",
"      Suri R, Grieve R, Normand C, et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002; 57:841.",
"     </a>",
"    </li>",
"    <li>",
"     Cystic Fibrosis Foundation Annual Patient Registry Report, 2011. Available at: Cystic Fibrosis Foundation Annual Patient Registry 2010 www.cff.org/research/ClinicalResearch/PatientRegistryReport (Accessed on February 27, 2012). (Accessed on January 23, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/34\">",
"      Cystic Fibrosis Foundation, Borowitz D, Robinson KA, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/35\">",
"      Berge MT, Wiel Ev, Tiddens HA, et al. DNase in stable cystic fibrosis infants: a pilot study. J Cyst Fibros 2003; 2:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/36\">",
"      Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/37\">",
"      Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/38\">",
"      Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009; :CD001506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/39\">",
"      Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012; 307:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/40\">",
"      Dasenbrook EC, Konstan MW. Inhaled hypertonic saline in infants and young children with cystic fibrosis. JAMA 2012; 307:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/41\">",
"      Elkins M, Dentice R. Timing of hypertonic saline inhalation for cystic fibrosis. Cochrane Database Syst Rev 2012; 2:CD008816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/42\">",
"      Dentice RL, Elkins MR, Bye PT. Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial. J Physiother 2012; 58:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/43\">",
"      Nash EF, Stephenson A, Ratjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2009; :CD007168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/44\">",
"      McIlwaine PM, Wong LT, Peacock D, Davidson AG. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr 1997; 131:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/45\">",
"      Hardy KA, Anderson BD. Noninvasive clearance of airway secretions. Respir Care Clin N Am 1996; 2:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/46\">",
"      Bradley JM, Moran FM, Elborn JS. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med 2006; 100:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/47\">",
"      Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev 2009; :CD006842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/48\">",
"      Sontag MK, Quittner AL, Modi AC, et al. Lessons learned from a randomized trial of airway secretion clearance techniques in cystic fibrosis. Pediatr Pulmonol 2010; 45:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/49\">",
"      Arias Llorente RP, Bouso&ntilde;o Garc&iacute;a C, D&iacute;az Mart&iacute;n JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros 2008; 7:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/50\">",
"      Oermann CM, Swank PR, Sockrider MM. Validation of an instrument measuring patient satisfaction with chest physiotherapy techniques in cystic fibrosis. Chest 2000; 118:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/51\">",
"      Schneiderman-Walker J, Pollock SL, Corey M, et al. A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. J Pediatr 2000; 136:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/52\">",
"      Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/53\">",
"      Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/54\">",
"      Saiman L, Mayer-Hamblett N, Campbell P, et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/55\">",
"      Shimizu T, Shimizu S, Hattori R, et al. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003; 168:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/56\">",
"      Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/57\">",
"      Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/58\">",
"      Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 2006; 61:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/59\">",
"      Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/60\">",
"      Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012; 11:CD002203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/61\">",
"      Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/62\">",
"      Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother 2007; 51:3677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/63\">",
"      Wagner T, Burns JL. Anti-inflammatory properties of macrolides. Pediatr Infect Dis J 2007; 26:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/64\">",
"      Ratjen F, Saiman L, Mayer-Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012; 142:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/65\">",
"      Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/66\">",
"      Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/67\">",
"      Arranz I, Mart&iacute;n-Su&aacute;rez A, Lanao JM, et al. Population pharmacokinetics of high dose ibuprofen in cystic fibrosis. Arch Dis Child 2003; 88:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/68\">",
"      Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/69\">",
"      Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995; 126:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/70\">",
"      Lai HC, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/71\">",
"      Hester KL, Powell T, Downey DG, et al. Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: a UK Survey. J Cyst Fibros 2007; 6:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/72\">",
"      Dovey M, Aitken ML, Emerson J, et al. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007; 132:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/73\">",
"      Bisgaard H, Pedersen SS, Nielsen KG, et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 156:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/74\">",
"      Nikolaizik WH, Sch&ouml;ni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996; 128:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/75\">",
"      van Haren EH, Lammers JW, Festen J, et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995; 89:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/76\">",
"      Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/77\">",
"      Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2012; 11:CD001915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/78\">",
"      Allen DB. Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr 2006; 53:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/79\">",
"      De Boeck K, De Baets F, Malfroot A, et al. Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients? Eur J Pediatr 2007; 166:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/80\">",
"      Sivan Y, Arce P, Eigen H, et al. A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity. J Allergy Clin Immunol 1990; 85:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/81\">",
"      Guevara JP, Ducharme FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006; :CD003558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/82\">",
"      Jain M, Thomson AH. Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis. J R Soc Med 2009; 102 Suppl 1:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/83\">",
"      Malfroot A, Adam G, Ciofu O, et al. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/84\">",
"      Robinson KA, Odelola OA, Saldanha IJ, McKoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2012; 2:CD007743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/85\">",
"      Mallory GB, Fullmer JJ, Vaughan DJ. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2005; :CD003884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/86\">",
"      Zinman R, Corey M, Coates AL, et al. Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients. J Pediatr 1989; 114:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/87\">",
"      Granton JT, Shapiro C, Kesten S. Noninvasive nocturnal ventilatory support in advanced lung disease from cystic fibrosis. Respir Care 2002; 47:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/88\">",
"      Young AC, Wilson JW, Kotsimbos TC, Naughton MT. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/89\">",
"      Davis PB, di Sant'Agnese PA. Assisted ventilation for patients with cystic fibrosis. JAMA 1978; 239:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/90\">",
"      Sood N, Paradowski LJ, Yankaskas JR. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001; 163:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/91\">",
"      Vedam H, Moriarty C, Torzillo PJ, et al. Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros 2004; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/92\">",
"      Ellaffi M, Vinsonneau C, Coste J, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005; 171:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/93\">",
"      Efrati O, Bylin I, Segal E, et al. Outcome of patients with cystic fibrosis admitted to the intensive care unit: is invasive mechanical ventilation a risk factor for death in patients waiting lung transplantation? Heart Lung 2010; 39:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/94\">",
"      Slieker MG, van Gestel JP, Heijerman HG, et al. Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis. Intensive Care Med 2006; 32:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/95\">",
"      Texereau J, Jamal D, Choukroun G, et al. Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. Respir Res 2006; 7:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/96\">",
"      Madden BP, Kariyawasam H, Siddiqi AJ, et al. Noninvasive ventilation in cystic fibrosis patients with acute or chronic respiratory failure. Eur Respir J 2002; 19:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/97\">",
"      Goldberg HJ, Deykin A. Advances in lung transplantation for patients who have cystic fibrosis. Clin Chest Med 2007; 28:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/98\">",
"      Hadjiliadis D. Special considerations for patients with cystic fibrosis undergoing lung transplantation. Chest 2007; 131:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/99\">",
"      Meachery G, De Soyza A, Nicholson A, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008; 63:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/100\">",
"      Rosenblatt RL. Lung transplantation in cystic fibrosis. Respir Care 2009; 54:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/101\">",
"      Aurora P, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report--2010. J Heart Lung Transplant 2010; 29:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/102\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. J Heart Lung Transplant 2010; 29:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/103\">",
"      Liou TG, Adler FR, Cahill BC, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001; 286:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/104\">",
"      Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745.",
"     </a>",
"    </li>",
"    <li>",
"     \"Talking about transplantation\" www.optn.org/sharedcontentdocuments/lung_allocation.professionalv4.pdf (Accessed on February 13, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/106\">",
"      Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/107\">",
"      Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008; 63:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/108\">",
"      Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/109\">",
"      De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010; 29:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/110\">",
"      Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/111\">",
"      Boyle MP. Update on maintaining bone health in cystic fibrosis. Curr Opin Pulm Med 2006; 12:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/112\">",
"      Liou TG, Adler FR, Cox DR, Cahill BC. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med 2007; 357:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/113\">",
"      Aurora P, Whitehead B, Wade A, et al. Lung transplantation and life extension in children with cystic fibrosis. Lancet 1999; 354:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/114\">",
"      Sweet SC, Aurora P, Benden C, et al. Lung transplantation and survival in children with cystic fibrosis: solid statistics--flawed interpretation. Pediatr Transplant 2008; 12:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/115\">",
"      Hofer M, Benden C, Inci I, et al. True survival benefit of lung transplantation for cystic fibrosis patients: the Zurich experience. J Heart Lung Transplant 2009; 28:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/116\">",
"      Smeritschnig B, Jaksch P, Kocher A, et al. Quality of life after lung transplantation: a cross-sectional study. J Heart Lung Transplant 2005; 24:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/117\">",
"      Kugler C, Fischer S, Gottlieb J, et al. Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant 2005; 24:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/118\">",
"      Nixon PA, Morris KA. Quality of life in pediatric heart, heart-lung, and lung transplant recipients. Int J Sports Med 2000; 21 Suppl 2:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/119\">",
"      Edenborough FP, Stableforth DE, Webb AK, et al. Outcome of pregnancy in women with cystic fibrosis. Thorax 1995; 50:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/120\">",
"      Goss CH, Rubenfeld GD, Otto K, Aitken ML. The effect of pregnancy on survival in women with cystic fibrosis. Chest 2003; 124:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/121\">",
"      McMullen AH, Pasta DJ, Frederick PD, et al. Impact of pregnancy on women with cystic fibrosis. Chest 2006; 129:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/122\">",
"      Cheng EY, Goss CH, McKone EF, et al. Aggressive prenatal care results in successful fetal outcomes in CF women. J Cyst Fibros 2006; 5:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/123\">",
"      Tonelli MR, Aitken ML. Pregnancy in cystic fibrosis. Curr Opin Pulm Med 2007; 13:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/124\">",
"      Thorpe-Beeston JG, Madge S, Gyi K, et al. The outcome of pregnancies in women with cystic fibrosis--single centre experience 1998-2011. BJOG 2013; 120:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/125\">",
"      Gillet D, de Braekeleer M, Bellis G, et al. Cystic fibrosis and pregnancy. Report from French data (1980-1999). BJOG 2002; 109:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/126\">",
"      Edenborough FP, Mackenzie WE, Stableforth DE. The outcome of 72 pregnancies in 55 women with cystic fibrosis in the United Kingdom 1977-1996. BJOG 2000; 107:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/127\">",
"      Gilljam M, Antoniou M, Shin J, et al. Pregnancy in cystic fibrosis. Fetal and maternal outcome. Chest 2000; 118:85.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Pulmonary disease in pregnancy. ACOG technical bulletin 224. Washington, DC. 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/129\">",
"      Whitelaw A, Butterfield A. High breast-milk sodium in cystic fibrosis. Lancet 1977; 2:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/130\">",
"      Canny GJ. Pregnancy in patients with cystic fibrosis. CMAJ 1993; 149:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/131\">",
"      Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/132\">",
"      Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/133\">",
"      Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/134\">",
"      Dusmet M, Winton TL, Kesten S, Maurer J. Previous intrapleural procedures do not adversely affect lung transplantation. J Heart Lung Transplant 1996; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/135\">",
"      Curtis HJ, Bourke SJ, Dark JH, Corris PA. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant 2005; 24:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/136\">",
"      Noppen M, Dhondt E, Mahler T, et al. Successful management of recurrent pneumothorax in cystic fibrosis by localized apical thoracoscopic talc poudrage. Chest 1994; 106:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/22/39274/abstract/137\">",
"      Quinton HB, O'Connor GT. Current issues in quality improvement in cystic fibrosis. Clin Chest Med 2007; 28:459.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6372 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39274=[""].join("\n");
var outline_f38_22_39274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20592751\">",
"      CFTR MODULATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BRONCHODILATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25485267\">",
"      Inhaled beta-2-adrenergic receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25485274\">",
"      Other bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AGENTS TO PROMOTE AIRWAY SECRETION CLEARANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inhaled DNase I (dornase alfa)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inhaled hypertonic saline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Comparing the use of DNase and hypertonic saline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inhaled N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHEST PHYSIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTI-INFLAMMATORY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Macrolide antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ibuprofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chronic administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Short-term treatment for acute pulmonary exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cromolyn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      VACCINATIONS AND PALIVIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Palivizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUPPLEMENTAL OXYGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NONINVASIVE POSITIVE PRESSURE VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INTENSIVE CARE UNIT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LUNG TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Timing of transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Limitations of transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      NONINFECTIOUS PULMONARY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Spontaneous pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6372\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6372|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/23/25981\" title=\"figure 1\">",
"      Survival of CF patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/0/18447\" title=\"figure 2\">",
"      CF colonization by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/59/17342\" title=\"figure 3\">",
"      Lung transplant survival by diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=related_link\">",
"      Cystic fibrosis: Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22503?source=related_link\">",
"      Cystic fibrosis: Prenatal genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43769?source=related_link\">",
"      Diffuse panbronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37896?source=related_link\">",
"      Hemoptysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3480?source=related_link\">",
"      Lung transplantation: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31192?source=related_link\">",
"      Lung transplantation: Disease-based choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/57/40850?source=related_link\">",
"      Patient information: Bronchiectasis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38327?source=related_link\">",
"      Respiratory syncytial virus infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/7/10360?source=related_link\">",
"      Role of systemic glucocorticoid therapy in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40793?source=related_link\">",
"      Spontaneous pneumothorax in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_22_39275="Chronic tension-type headache criteria";
var content_f38_22_39275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chronic tension-type headache diagnostic criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Description:",
"        </strong>",
"        A disorder evolving from episodic tension-type headache, with daily or very frequent episodes of headache lasting minutes to days. The pain is typically bilateral, pressing or tightening in quality, and of mild to moderate intensity, and it does not worsen with routine physical activity. There may be nausea, photophobia or phonophobia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Diagnostic criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Headache occurring on &ge;15 days per month on average for more than three months (&ge;180 days per year) and fulfilling criteria B through D",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B. Headache lasts hours or may be continuous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. Headache has at least two of the following characteristics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Bilateral location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Pressing/tightening (non-pulsating) quality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Mild or moderate intensity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        4. Not aggravated by routine physical activity such as walking or climbing stairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D. Both of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. No more than one of photophobia, phonophobia or mild nausea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Neither moderate or severe nausea nor vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E. Not attributed to another disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Headache classification subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39275=[""].join("\n");
var outline_f38_22_39275=null;
var title_f38_22_39276="Classification of DR";
var content_f38_22_39276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of diabetic retinopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nonproliferative Diabetic Retinopathy (NPDR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mild NPDR:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        At least one microaneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Criteria not met for other levels of DR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Moderate NPDR:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Hemorrhage/microaneurysm &ge; standard photograph #2A",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Soft exudates (cotton wool spots), venous beading, and intraretinal microvascular abnormalities definitely present",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Criteria not met for severe NPDR, very severe NPDR, or PDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Severe NPDR:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Hemorrhage/microaneurysm &ge; standard photograph #2A in all 4 quadrants",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Venous beading in at least two quadrants",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Intraretinal microvascular abnormalities &ge; standard photograph #8A in at least one quadrant",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Very severe NPDR:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any two or more of criteria for severe NPDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Criteria not met for PDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Proliferative Diabetic Retinopathy (PDR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Early PDR:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        New vessels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Criteria not met for high-risk PDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        High-risk PDR:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Neovascularization of the disk &ge;1/3 to 1/2 disk area",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Neovascularization of the disk and vitreous or preretinal hemorrhage",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Neovascularization elsewhere &ge;1/2 disk area AND vitreous or pretretinal hemorrhage",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Severe PDR:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Posterior fundus obscured by preretinal or vitreous hemorrhage",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Center of macula detached",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinically Significant Macular Edema (CSME)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Thickening of the retina &le;500 &micro;m from the center of the macula",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Hard exudates and adjacent retinal thickening &le;500 &micro;m from macular center",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Zone of retinal thickening at least 1 disc area in size located &le;1 disc diameter from the center of the macula",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136:122.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39276=[""].join("\n");
var outline_f38_22_39276=null;
var title_f38_22_39277="Healthy weight nutrition tips A";
var content_f38_22_39277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50935%7EPEDS%2F62686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50935%7EPEDS%2F62686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for maintaining a healthy weight: Nutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phase I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Choose sugar-free beverages or low-fat milk only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choose sugar-free beverages, water or low-fat (skim, one-half percent, and 1 percent) milk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limit milk to 16 to 24 ounces per day. Avoid flavored milks, including fat-free versions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Have fast food no more than once a week, and try the following healthier options:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Choose plain hamburger kid's meal with water, diet soda, or skim milk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Try a grilled chicken sandwich ordered without mayonnaise with a piece of fruit from home.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Try a 6-inch, low-fat Subway sandwich (ordered without mayonnaise, cheese, or oils), with baked chips or pretzels.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid burgers with double meat, cheese, bacon, mayonnaise, and super-sized french fries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Choose three meals with one snack per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healthy breakfast ideas: two pieces whole wheat toast with a glass of skim milk; small bowl of cereal such as bran flakes, Cheerios or old-fashioned oat meal with skim milk; or a fat-free yogurt and a piece of fresh fruit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Healthy snacks include fresh fruit, fat-free yogurt, or low-fat popcorn.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limit snacks to one serving size.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Try the Plate Method at dinner. Design a dinner plate with one-half a plate of vegetables, one-quarter plate of lean meat, and one-quarter plate of starch or starchy vegetables (potatoes, corn, or peas) (see",
"        <a href=\"file://www.choosemyplate.gov\" target=\"_blank\">",
"         www.choosemyplate.gov",
"        </a>",
"        ). Avoid second helpings.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for maintaining a healthy weight: nutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"3\">",
"       Phase II",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Eat a variety of foods.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Eat fruits, vegetables, whole grain breads, cereals, rice, and pastas; low-fat and fat-free dairy products; lean chicken, turkey, fish, and legumes; and healthy fats. Use a small amount of added fats and sugars. Avoid fried foods. See the Low-fat, Low-Sugar Eating Guidelines for a list of food choices and sample menus.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Eat proper portion sizes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Young children and inactive girls should choose the lower number of servings from each food group. Most active school-aged children and teen girls, as well as inactive teen boys should choose the middle number of servings. Active teen boys and some very active teen girls should choose the higher number of servings from each food group.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Group",
"      </td>",
"      <td class=\"subtitle2\">",
"       Number of servings per day",
"      </td>",
"      <td class=\"subtitle2\">",
"       Serving size",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bread, cereal, rice, pasta and starchy vegetable",
"      </td>",
"      <td>",
"       6 to 11",
"      </td>",
"      <td>",
"       1 slice whole wheat bread; 1/2 cup cooked whole-grain cereal, brown rice, or whole wheat pasta",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fruit",
"      </td>",
"      <td>",
"       2 to 4",
"      </td>",
"      <td>",
"       1 small piece fruit or 1/2 banana; 1 cup fresh fruit such as melon or berries; 1/2 cup canned fruit; four ounces juice; two tablespoons dried fruit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vegetable",
"      </td>",
"      <td>",
"       3 to 5",
"      </td>",
"      <td>",
"       1/2 cup cooked vegetables or vegetable juice; 1 cup raw vegetables",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Milk, yogurt, and cheese",
"      </td>",
"      <td>",
"       2 to 4",
"      </td>",
"      <td>",
"       1 cup skim or 1 percent milk; 1 cup fat-free or low-fat yogurt; 1 ounce fat-free or reduced fat cheese",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meat, poultry, fish, dry beans, eggs and nuts",
"      </td>",
"      <td>",
"       2 to 3",
"      </td>",
"      <td>",
"       2 to 3 ounces of skinless chicken, turkey, or fish; 1/2 cup beans or tofu; 1/4 cup nuts; 2 tablespoons nut butter; 1/4 cup egg whites or egg substitute",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fats, oils, sweets",
"      </td>",
"      <td>",
"       Use a small amount",
"      </td>",
"      <td>",
"       1 teaspoon butter, margarine, mayonnaise, oil, or sugar; 1 tablespoon salad dressing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Stock your house with healthful food choices.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Eliminate unhealthful food choices from your house including low-fat cookies, cakes and ice cream as these foods are often enriched with sugar. Instead, stock your house with fresh fruit, cut up vegetables and fat-free or low-fat yogurt. Children can choose between an apple or yogurt for a snack, not an apple or potato chips.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Limit restaurant eating to 1 time per week.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Restaurants provide large food portions. Split entrees or plan to take half home. If time is an issue, choose low-fat frozen dinners with bagged salad and/or a side of frozen vegetables.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Take your lunch to school.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Pack a lunch with 2 ounces of lean meat or 1 ounce low-fat or fat-free cheese on whole grain bread with one serving of fruit, vegetables and fat-free milk or yogurt. Avoid eating breakfast at school. Instead, choose a bowl of whole grain cereal at home.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39277=[""].join("\n");
var outline_f38_22_39277=null;
var title_f38_22_39278="Bunny lines lateral view";
var content_f38_22_39278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    \"Bunny lines\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wrinkles on the dorsal and lateral nose can occur during contraction of the upper nasalis muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39278=[""].join("\n");
var outline_f38_22_39278=null;
var title_f38_22_39279="Cryptogenic organizing pneumonia CT II";
var content_f38_22_39279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptogenic organizing pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sixty-two-year-old man with a one-month history of dyspnea with exertion, fatigue, and weight loss. High resolution CT scan shows patchy airspace consolidation in the right lower lobes (multiple similar opacities were seen in both lungs). Air bronchograms also are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_22_39279=[""].join("\n");
var outline_f38_22_39279=null;
